Compounds > danoprevir
Page last updated: 2024-08-02 19:15:41

danoprevir

Description

Cross-References

ID SourceID
PubMed CID129010331
PubMed CID11285588
CHEMBL ID258734
SCHEMBL ID2289034
MeSH IDM0552073

Synonyms (47)

Synonym
850876-88-9
danoprevir ,
HMS3654C18
itmn-191;r7227;ro5190591;rg7227
itmn-191
rg7227
r7227 ,
r-05190591
ro5190591
CHEMBL258734
r05190591
ro-5190591
itmn 191
rg 7227
r 7227
911z9pcq5f ,
r 05190591
itmn191
itmn b
intermune itmn-191
danoprevir [usan:inn]
rg-7227
r7227 cpd
ganovo
unii-911z9pcq5f
S1183
danoprevir [usan]
danoprevir [who-dd]
danoprevir [inn]
MLS006011139
smr004702916
SCHEMBL2289034
(2r,6s,13as,14ar,16as,z)-6-(tert-butoxycarbonylamino)-14a-(cyclopropylsulfonylcarbamoyl)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-2-yl 4-fluoroisoindoline-2-carboxylate
rg7227, itmn-191, ro5190591
4-fluoro-1,3-dihydro-2h-isoindole-2-carboxylic acid (2r,6s,13as,14ar,16as)-14a-(((cyclopropylsulfonyl)amino)carbonyl)-6-(((1,1-dimet hylethoxy)carbonyl)amino)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a
J-515317
SW219089-1
DB11779
(2r,6s,13as,14ar,16as,z)-6-((tert-butoxycarbonyl)amino)-14a-((cyclopropylsulfonyl)carbamoyl)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-2-yl 4-fluoroisoindoline-2-carboxylate
[(1s,4r,6s,7z,14s,18r)-4-(cyclopropylsulfonylcarbamoyl)-14-[(2-methylpropan-2-yl)oxycarbonylamino]-2,15-dioxo-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-en-18-yl] 4-fluoro-1,3-dihydroisoindole-2-carboxylate
danoprevir (itmn-191)
danoprevir (rg7227,itmn-191,ro5190591
bdbm50495950
CCG-270417
Q27271364
NCGC00346498-06
AKOS037515841

Protein Targets (9)

Inhibition Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
Genome polyprotein IC500.0002AID1645923
NS3 protease Ki0.0448AID1070607
Non-structural protein 4A IC500.0002AID1645923
NS3 protease Hepatitis C virus subtype 1bKi0.0090AID1299188

Other Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
Cytochrome P450 1A2Homo sapiens (human)INH25.0000AID1070637
Cytochrome P450 3A4Homo sapiens (human)INH12.0000AID1070633
Cytochrome P450 2D6Homo sapiens (human)INH25.0000AID1070634
Cytochrome P450 2C9 Homo sapiens (human)INH25.0000AID1070636
Cytochrome P450 2C19Homo sapiens (human)INH25.0000AID1070635

Bioassays (164)

Assay IDTitleYearJournalArticle
AID1071918Inhibition of Hepatitis C virus genotype 1b full-length NS3/NS4A protease assessed as equilibrium dissociation constant by surface plasmon resonance biosensor-based interaction kinetic analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID711502Inhibition of HCV 1b NS3 protease2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
ISSN: 1520-4804		Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.
AID1070641Antiviral activity against Hepatitis C virus genotype 2 infected in human HuH7 cells assessed as decrease in replicon RNA level after 2 days by TaqMan Gold RT-PCR analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID719472Antiviral activity against HCV subtype 1b expressing wild type NS3/4A protease infected in ET cells after 72 hrs2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
ISSN: 1464-3405		Synthesis and antiviral activity of novel HCV NS3 protease inhibitors with P4 capping groups.
AID1698001Lipophilicity, log D of the compound at pH 7.4 by by shake flask method2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
ISSN: 1520-4804
AID584109Ratio of EC50 for wild type HCV1b harboring NS3 protease gene to EC50 for HCV1b harboring NS3 protease Q80K mutant2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
ISSN: 1098-6596		Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors.
AID656670Antiviral activity against Hepatitis C virus genotype 1b expressing wild type NS3/4A protease infected in HuH7 cells2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
ISSN: 1464-3405		Discovery of novel P3-oxo inhibitor of hepatitis C virus NS3/4A serine protease.
AID1070636Inhibition of CYP2C9 (unknown origin)2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID539678Inhibition of HCV 1a NS3/4A protease by FRET assay2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
ISSN: 1464-3405		Synthesis and biological evaluations of P4-benzoxaborole-substituted macrocyclic inhibitors of HCV NS3 protease.
AID1071916Inhibition of Hepatitis C virus genotype 3a full-length NS3 protease assessed as equilibrium dissociation constant by surface plasmon resonance biosensor-based interaction kinetic analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID1070621Metabolic stability in human hepatocytes assessed as extraction ratio at 1 uM2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID1070622Metabolic stability in rat hepatocytes assessed as extraction ratio at 1 uM2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID1070635Inhibition of CYP2C19 (unknown origin)2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID584110Ratio of EC50 for wild type HCV1b harboring NS3 protease gene to EC50 for HCV1b harboring NS3 protease Q80K, T54S mutant2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
ISSN: 1098-6596		Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors.
AID538710Antiviral activity against HCV genotype 1b transfected in human hepatoma cell assessed as inhibition of viral replication2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
ISSN: 1464-3405		Synthesis of new acylsulfamoyl benzoxaboroles as potent inhibitors of HCV NS3 protease.
AID1071913Inhibition of Hepatitis C virus genotype 1b full-length NS3 protease assessed as overall/observed affinity by surface plasmon resonance biosensor-based interaction kinetic analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID656676Antiviral activity against Hepatitis C virus genotype 1b expressing NS3/4A protease R155K mutant infected in HuH7 cells2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
ISSN: 1464-3405		Discovery of novel P3-oxo inhibitor of hepatitis C virus NS3/4A serine protease.
AID521266Selectivity ratio of EC50 for Hepatitis C virus genotype 1b N expressing NS3 D168V mutant infected in human HuH7 cells to EC50 for Hepatitis C virus genotype 1b N expressing wild type NS3 infected in human HuH7 cells2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
ISSN: 0066-4804		Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID664168Resistance index, ratio of EC50 for Hepatitis C virus subtype 1b harboring protease D168A mutant to EC50 for wild type Hepatitis C virus subtype 1b2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
ISSN: 1520-4804		Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
AID539674Metabolic absorption in rat2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
ISSN: 1464-3405		Synthesis and biological evaluations of P4-benzoxaborole-substituted macrocyclic inhibitors of HCV NS3 protease.
AID1070640Antiviral activity against Hepatitis C virus genotype 1b infected in human HuH7 cells assessed as decrease in replicon RNA level after 2 days by TaqMan Gold RT-PCR analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID719471Antiviral activity against HCV subtype 1b expressing NS3/4A A156S mutant protease infected in ET cells after 72 hrs2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
ISSN: 1464-3405		Synthesis and antiviral activity of novel HCV NS3 protease inhibitors with P4 capping groups.
AID538713Metabolic absorption in Sprague-Dawley rat at 5 mg/kg, po2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
ISSN: 1464-3405		Synthesis of new acylsulfamoyl benzoxaboroles as potent inhibitors of HCV NS3 protease.
AID664167Antiviral activity against Hepatitis C virus subtype 1b harboring protease R155K mutant by transient replicon assay2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
ISSN: 1520-4804		Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
AID1070602Ratio of EC50 for Hepatitis C virus harboring NS3/4A protease A156T mutant gene to EC50 for Hepatitis C virus harboring wild type NS3/4A protease infected in human HuH7 cells2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID711501Inhibition of HCV 1a NS3 protease2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
ISSN: 1520-4804		Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.
AID538708Inhibition of HCV genotype 1 a NS3/4A protease by FRET assay2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
ISSN: 1464-3405		Synthesis of new acylsulfamoyl benzoxaboroles as potent inhibitors of HCV NS3 protease.
AID1070616Aqueous solubility of the compound at pH 6.5 by modified shake-flask method2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID1299190Cytotoxicity against human HuH7 cells2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
ISSN: 1464-3391		Discovery of pyrazinone based compounds that potently inhibit the drug-resistant enzyme variant R155K of the hepatitis C virus NS3 protease.
AID656673Antiviral activity against Hepatitis C virus genotype 1b expressing NS3/4A protease A156V mutant infected in HuH7 cells2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
ISSN: 1464-3405		Discovery of novel P3-oxo inhibitor of hepatitis C virus NS3/4A serine protease.
AID711500Antiviral activity against HCV by cell based replicon assay2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
ISSN: 1520-4804		Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.
AID1071914Inhibition of Hepatitis C virus genotype 1a full-length NS3/NS4A protease assessed as overall/observed affinity by surface plasmon resonance biosensor-based interaction kinetic analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID521264Selectivity ratio of EC50 for Hepatitis C virus genotype 1b N expressing NS3 V170A mutant infected in human HuH7 cells to EC50 for Hepatitis C virus genotype 1b N expressing wild type NS3 infected in human HuH7 cells2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
ISSN: 0066-4804		Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID1070613Plasma clearance in rat assessed as extraction ratio2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID664166Antiviral activity against wild type Hepatitis C virus subtype 1b by transient replicon assay2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
ISSN: 1520-4804		Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
AID656668Antiviral activity against Hepatitis C virus genotype 1b infected in HuH7 cells2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
ISSN: 1464-3405		Discovery of novel P3-oxo inhibitor of hepatitis C virus NS3/4A serine protease.
AID719466Antiviral activity against HCV subtype 1b expressing NS3/4A R115K mutant protease infected in ET cells after 72 hrs2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
ISSN: 1464-3405		Synthesis and antiviral activity of novel HCV NS3 protease inhibitors with P4 capping groups.
AID322946Inhibition of HCV NS3 protease by FRET assay2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
ISSN: 1464-3391		Hepatitis C virus NS3 protease inhibitors comprising a novel aromatic P1 moiety.
AID322947Antiviral activity against Hepatitis C virus infected human hepatoma cells by replicon assay2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
ISSN: 1464-3391		Hepatitis C virus NS3 protease inhibitors comprising a novel aromatic P1 moiety.
AID521268Selectivity ratio of EC50 for Hepatitis C virus genotype 1b N expressing NS3 A156S mutant infected in human HuH7 cells to EC50 for Hepatitis C virus genotype 1b N expressing wild type NS3 infected in human HuH7 cells2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
ISSN: 0066-4804		Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID584103Ratio of EC50 for wild type HCV1b harboring NS3 protease gene to EC50 for HCV1b A25 harboring NS3 protease T40A, T54S, V55I, I64L, P67S, Q80K, Q88H, S90A, L153I mutant2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
ISSN: 1098-6596		Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors.
AID656669Antiviral activity against Hepatitis C virus genotype 1a infected in HuH7 cells2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
ISSN: 1464-3405		Discovery of novel P3-oxo inhibitor of hepatitis C virus NS3/4A serine protease.
AID1071915Inhibition of Hepatitis C virus genotype 1a full-length NS3 protease assessed as overall/observed affinity by surface plasmon resonance biosensor-based interaction kinetic analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID538714Oral bioavailability in Sprague-Dawley rat at 5 mg/kg2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
ISSN: 1464-3405		Synthesis of new acylsulfamoyl benzoxaboroles as potent inhibitors of HCV NS3 protease.
AID612410Inhibition of HCV NS3 protease2011Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16
ISSN: 1464-3391		P2-P1' macrocyclization of P2 phenylglycine based HCV NS3 protease inhibitors using ring-closing metathesis.
AID584102Antiviral activity against HCV1b Con1 harboring NS3 protease gene infected in human Huh7/Lunet cells assessed as inhibition of viral replication after 3 days by luciferase based transient-transfection assay2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
ISSN: 1098-6596		Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors.
AID1698007Ratio of drug level in human blood to plasma administered through iv dosing by LC-MS/MS analysis2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
ISSN: 1520-4804
AID1070612Volume of distribution at steady state in Sprague-Dawley rat at 30 mg/kg, po by HPLC-MS/MS analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID1070631Time-dependent inhibition of CYP3A4 (unknown origin)2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID1071917Inhibition of Hepatitis C virus genotype 1b NS3 protease domain assessed as equilibrium dissociation constant by surface plasmon resonance biosensor-based interaction kinetic analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID1070605Antiviral activity against Hepatitis C virus genotype 1a isolate Con1 harboring NS3/4A protease A156T mutant gene infected in human HuH7 cells assessed as inhibition of HCV replicon replication by luciferase assay2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID1070647Inhibition of Hepatitis C virus genotype 1b NS3/4A protease using Ac-DE-Dap(QXL520)-EE-Abu-psi-[COO]-AS-Cys(5-FAMsp)-NH2 as substrate by FRET analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID664169Resistance index, ratio of EC50 for Hepatitis C virus subtype 1b harboring protease D168V mutant to EC50 for wild type Hepatitis C virus subtype 1b2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
ISSN: 1520-4804		Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
AID1070648Inhibition of Hepatitis C virus genotype 1a NS3/4A protease using Ac-DE-Dap(QXL520)-EE-Abu-psi-[COO]-AS-Cys(5-FAMsp)-NH2 as substrate by FRET analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID1070632Time-dependent induction of CYP3A4 (unknown origin)2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID1070606Antiviral activity against Hepatitis C virus genotype 1a isolate Con1 harboring wild type NS3/4A protease infected in human HuH7 cells assessed as inhibition of HCV replicon replication by luciferase assay2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID1071919Inhibition of Hepatitis C virus genotype 1b full-length NS3 protease assessed as equilibrium dissociation constant by surface plasmon resonance biosensor-based interaction kinetic analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID1698000Apparent permeability in dog MDCKII-LE cells at pH 7.42020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
ISSN: 1520-4804
AID1070609Ratio of AUC (0 to 24 hrs) in liver to plasma in Sprague-Dawley rat at 30 mg/kg, po by HPLC-MS/MS analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID664163Antiviral activity against Hepatitis C virus subtype 1b harboring protease A156V mutant by transient replicon assay2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
ISSN: 1520-4804		Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
AID521279Antiviral activity against Hepatitis C virus genotype 1b N expressing NS3 A156T mutant infected in human HuH7 cells2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
ISSN: 0066-4804		Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID1070645Inhibition of Hepatitis C virus genotype 5 NS3/4A protease using Ac-DE-Dap(QXL520)-EE-Abu-psi-[COO]-AS-Cys(5-FAMsp)-NH2 as substrate by FRET analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID656667Inhibition of Hepatitis C virus genotype 1a NS3/4A protease using Ac-DE-Dap(QXL520)-EE-Abu-psi-COO]-AS-C(5-FAMsp)-NH2 as substrate by FRET analysis2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
ISSN: 1464-3405		Discovery of novel P3-oxo inhibitor of hepatitis C virus NS3/4A serine protease.
AID1698010Hepatic clearance in human administered through iv dosing2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
ISSN: 1520-4804
AID1070651Inhibition of Hepatitis C virus full-length NS3/4A protease assessed as quenched-fluorogenic RET-S1 substrate cleavage incubated for 10 mins prior to substrate addition by FRET analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID719469Antiviral activity against HCV subtype 1b expressing NS3/4A A156V mutant protease infected in ET cells after 72 hrs2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
ISSN: 1464-3405		Synthesis and antiviral activity of novel HCV NS3 protease inhibitors with P4 capping groups.
AID664157Resistance index, ratio of EC50 for Hepatitis C virus subtype 1b harboring protease R155K mutant to EC50 for wild type Hepatitis C virus subtype 1b2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
ISSN: 1520-4804		Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
AID1070646Inhibition of Hepatitis C virus genotype 4 NS3/4A protease using Ac-DE-Dap(QXL520)-EE-Abu-psi-[COO]-AS-Cys(5-FAMsp)-NH2 as substrate by FRET analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID521270Selectivity ratio of EC50 for Hepatitis C virus genotype 1b N expressing NS3 A156T mutant infected in human HuH7 cells to EC50 for Hepatitis C virus genotype 1b N expressing wild type NS3 infected in human HuH7 cells2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
ISSN: 0066-4804		Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID711499Inhibition of HCV 3a NS3 protease2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
ISSN: 1520-4804		Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.
AID664164Antiviral activity against Hepatitis C virus subtype 1b harboring protease A156T mutant by transient replicon assay2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
ISSN: 1520-4804		Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
AID584101Ratio of EC50 for wild type HCV1b harboring NS3 protease gene to EC50 for HCV1b B13 harboring NS3 protease R26K, V46I, Q80L mutant2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
ISSN: 1098-6596		Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors.
AID1552078Binding affinity to HCV NS3/4a protease assessed as compound-protein adduct formation per mg protein using radiolabelled compound2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
ISSN: 1464-3405		Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi
AID1071921Inhibition of Hepatitis C virus genotype 1a full-length NS3 protease assessed as equilibrium dissociation constant by surface plasmon resonance biosensor-based interaction kinetic analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID538709Antiviral activity against HCV genotype 1a transfected in human hepatoma cell assessed as inhibition of viral replication2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
ISSN: 1464-3405		Synthesis of new acylsulfamoyl benzoxaboroles as potent inhibitors of HCV NS3 protease.
AID521277Selectivity ratio of EC50 for Hepatitis C virus genotype 1b N expressing NS3 R155K mutant infected in human HuH7 cells to EC50 for Hepatitis C virus genotype 1b N expressing wild type NS3 infected in human HuH7 cells at >10 nM2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
ISSN: 0066-4804		Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID1070619Metabolic stability in dog hepatocytes assessed as extraction ratio at 1 uM2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID664161Antiviral activity against Hepatitis C virus subtype 1b harboring protease D168V mutant by transient replicon assay2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
ISSN: 1520-4804		Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
AID521269Selectivity ratio of EC50 for Hepatitis C virus genotype 1b N expressing NS3 V36M/R155K double mutant infected in human HuH7 cells to EC50 for Hepatitis C virus genotype 1b N expressing wild type NS3 infected in human HuH7 cells2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
ISSN: 0066-4804		Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID1070634Inhibition of CYP2D6 (unknown origin)2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID711494Ratio of drug level in liver to plasma of monkey2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
ISSN: 1520-4804		Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.
AID719468Antiviral activity against HCV subtype 1b expressing NS3/4A D168A mutant protease infected in ET cells after 72 hrs2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
ISSN: 1464-3405		Synthesis and antiviral activity of novel HCV NS3 protease inhibitors with P4 capping groups.
AID1071920Inhibition of Hepatitis C virus genotype 1a full-length NS3/NS4A protease assessed as equilibrium dissociation constant by surface plasmon resonance biosensor-based interaction kinetic analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID719474Antiviral activity against HCV subtype 1a infected in human hepatoma cells2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
ISSN: 1464-3405		Synthesis and antiviral activity of novel HCV NS3 protease inhibitors with P4 capping groups.
AID1070626Ratio of drug level in liver to plasma in rat2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID1698011Fraction unbound in human plasma2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
ISSN: 1520-4804
AID1070637Inhibition of CYP1A2 (unknown origin)2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID711496Inhibition of HCV4 NS3 protease2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
ISSN: 1520-4804		Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.
AID664158Inhibition of HCV 1a protease 1a domain2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
ISSN: 1520-4804		Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
AID711495Inhibition of HCV6 NS3 protease2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
ISSN: 1520-4804		Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.
AID521267Selectivity ratio of EC50 for Hepatitis C virus genotype 1b N expressing NS3 A156V mutant infected in human HuH7 cells to EC50 for Hepatitis C virus genotype 1b N expressing wild type NS3 infected in human HuH7 cells2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
ISSN: 0066-4804		Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID1070611AUC (0 to 24 hrs) in Sprague-Dawley rat liver at 30 mg/kg, po by HPLC-MS/MS analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID491860Inhibition of HCV NS3 protease by FRET assay2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
ISSN: 1464-3391		Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents.
AID584108Ratio of EC50 for wild type HCV1b harboring NS3 protease gene to EC50 for HCV1b harboring NS3 protease T54S mutant2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
ISSN: 1098-6596		Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors.
AID1070627Ratio of drug level in liver to plasma in dog2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID1070607Inhibition of Hepatitis C virus genotype 1a NS3/4A protease A156T mutant expressed in Escherichia coli BL21 (DE3) cells assessed as substrate cleavage using Ac-DE-Dap(QXL520)-EE-Abu-psi-[COO]AS-C(5-FAMsp)-NH2 as substrate by plate reader analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID656671Antiviral activity against Hepatitis C virus genotype 1b expressing NS3/4A protease A156S mutant infected in HuH7 cells2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
ISSN: 1464-3405		Discovery of novel P3-oxo inhibitor of hepatitis C virus NS3/4A serine protease.
AID1299188Inhibition of full-length HCV genotype 1a NS3 protease R155K mutant using Ac-DED(Edans)EEAbu-psi-[COO]ASK(Dabcyl)-NH2 as substrate by FRET assay2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
ISSN: 1464-3391		Discovery of pyrazinone based compounds that potently inhibit the drug-resistant enzyme variant R155K of the hepatitis C virus NS3 protease.
AID1070639Antiviral activity against Hepatitis C virus genotype 3 infected in human HuH7 cells assessed as decrease in replicon RNA level after 2 days by TaqMan Gold RT-PCR analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID1070644Inhibition of Hepatitis C virus genotype 6 NS3/4A protease using Ac-DE-Dap(QXL520)-EE-Abu-psi-[COO]-AS-Cys(5-FAMsp)-NH2 as substrate by FRET analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID539677Antiviral activity against HCV 1a infected in human Huh-7 cells after 48hrs by luciferase assay2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
ISSN: 1464-3405		Synthesis and biological evaluations of P4-benzoxaborole-substituted macrocyclic inhibitors of HCV NS3 protease.
AID719470Antiviral activity against HCV subtype 1b expressing NS3/4A A156T mutant protease infected in ET cells after 72 hrs2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
ISSN: 1464-3405		Synthesis and antiviral activity of novel HCV NS3 protease inhibitors with P4 capping groups.
AID1299187Inhibition of wild-type full-length HCV genotype 1a NS3 protease using Ac-DED(Edans)EEAbu-psi-[COO]ASK(Dabcyl)-NH2 as substrate by FRET assay2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
ISSN: 1464-3391		Discovery of pyrazinone based compounds that potently inhibit the drug-resistant enzyme variant R155K of the hepatitis C virus NS3 protease.
AID612408Antiviral activity against HCV2011Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16
ISSN: 1464-3391		P2-P1' macrocyclization of P2 phenylglycine based HCV NS3 protease inhibitors using ring-closing metathesis.
AID1070617Aqueous solubility of the compound at pH 7.4 by modified shake-flask method2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID584105Antiviral activity against HCV1b harboring Q80Q polymorphism in NS3 protease gene infected in human Huh7/Lunet cells assessed as inhibition of viral replication after 3 days by luciferase based transient-transfection assay2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
ISSN: 1098-6596		Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors.
AID711498Inhibition of HCV 2b NS3 protease2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
ISSN: 1520-4804		Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.
AID1299189Antiviral activity against HCV infected in human HuH7 cells by cell based replicon assay2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
ISSN: 1464-3391		Discovery of pyrazinone based compounds that potently inhibit the drug-resistant enzyme variant R155K of the hepatitis C virus NS3 protease.
AID1698006Ratio of drug level in cynomolgus monkey blood to plasma administered through iv dosing by LC-MS/MS analysis2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
ISSN: 1520-4804
AID1070630Inhibition of human ERG at 10 uM2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID1071912Inhibition of Hepatitis C virus genotype 1b full-length NS3/NS4A protease assessed as overall/observed affinity by surface plasmon resonance biosensor-based interaction kinetic analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID1645924Antiviral activity against HCV2019European journal of medicinal chemistry, Feb-15, Volume: 164ISSN: 1768-3254A review on HCV inhibitors: Significance of non-structural polyproteins.
AID538711Clearance in Sprague-Dawley rat at 1 mg/kg, iv2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
ISSN: 1464-3405		Synthesis of new acylsulfamoyl benzoxaboroles as potent inhibitors of HCV NS3 protease.
AID1070624Ratio of drug level in liver to plasma in monkey2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID491861Antiviral activity against HCV 1B infected in human Huh7 cells by firefly luciferase reporter gene assay2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
ISSN: 1464-3391		Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents.
AID1070633Inhibition of CYP3A4 (unknown origin)2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID521273Selectivity ratio of EC50 for Hepatitis C virus genotype 1b N expressing NS3 V36M mutant infected in human HuH7 cells to EC50 for Hepatitis C virus genotype 1b N expressing wild type NS3 infected in human HuH7 cells2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
ISSN: 0066-4804		Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID1070601Dissociation constant, pKa of the compound2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID711497Inhibition of HCV5 NS3 protease2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
ISSN: 1520-4804		Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.
AID1070608Inhibition of Hepatitis C virus genotype 1a wild type NS3/4A protease expressed in Escherichia coli BL21 (DE3) cells assessed as substrate cleavage using Ac-DE-Dap(QXL520)-EE-Abu-psi-[COO]AS-C(5-FAMsp)-NH2 as substrate by plate reader analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID539676Antiviral activity against HCV 1b infected in human Huh-7 cells after 48hrs by luciferase assay2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
ISSN: 1464-3405		Synthesis and biological evaluations of P4-benzoxaborole-substituted macrocyclic inhibitors of HCV NS3 protease.
AID584106Antiviral activity against HCV1b harboring Q80K polymorphism in NS3 protease gene infected in human Huh7/Lunet cells assessed as inhibition of viral replication after 3 days by luciferase based transient-transfection assay2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
ISSN: 1098-6596		Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors.
AID1070615Permeability from apical to basolateral side of human Caco2 cells2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID1070642Inhibition of Hepatitis C virus genotype 3a NS3/4A protease using Ac-DE-Dap(QXL520)-EE-Abu-psi-[COO]-AS-Cys(5-FAMsp)-NH2 as substrate by FRET analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID521274Antiviral activity against wild-type Hepatitis C virus genotype 1b N infected in human Huh7 cells2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
ISSN: 0066-4804		Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID664160Antiviral activity against Hepatitis C virus subtype 1a by stable replicon assay2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
ISSN: 1520-4804		Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
AID1070603Antiviral activity against Hepatitis C virus harboring NS3/4A protease A156T mutant gene infected in human HuH7 cells assessed as inhibition of HCV subgenomic replicon replication after 72 hrs by ELISA2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID1070614Efflux ratio of permeability from basolateral to apical side over apical to basolateral side in human Caco2 cells2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID521265Selectivity ratio of EC50 for Hepatitis C virus genotype 1b N expressing NS3 D168A mutant infected in human HuH7 cells to EC50 for Hepatitis C virus genotype 1b N expressing wild type NS3 infected in human HuH7 cells2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
ISSN: 0066-4804		Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID656674Antiviral activity against Hepatitis C virus genotype 1b expressing NS3/4A protease D158A mutant infected in HuH7 cells2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
ISSN: 1464-3405		Discovery of novel P3-oxo inhibitor of hepatitis C virus NS3/4A serine protease.
AID664162Antiviral activity against Hepatitis C virus subtype 1b harboring protease D168A mutant by transient replicon assay2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
ISSN: 1520-4804		Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
AID664165Antiviral activity against Hepatitis C virus subtype 1b harboring protease A156S mutant by transient replicon assay2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
ISSN: 1520-4804		Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
AID1070643Inhibition of Hepatitis C virus genotype 2b NS3/4A protease using Ac-DE-Dap(QXL520)-EE-Abu-psi-[COO]-AS-Cys(5-FAMsp)-NH2 as substrate by FRET analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID719475Inhibition of HCV subtype 1a NS3/4A protease (Ac-DE-Dap(QXL520)-EE-Abu-psi-[COO]-ASC(5-FAMsp)-NH2 as substrate by FRET analysis2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
ISSN: 1464-3405		Synthesis and antiviral activity of novel HCV NS3 protease inhibitors with P4 capping groups.
AID1070638Cytotoxicity against human MT4 cells2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID584107Ratio of EC50 for HCV1b harboring Q80K polymorphism in NS3 protease gene to EC50 for HCV1b harboring Q80Q polymorphism in NS3 protease gene2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
ISSN: 1098-6596		Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors.
AID1070610AUC (0 to 24 hrs) in Sprague-Dawley rat plasma at 30 mg/kg, po by HPLC-MS/MS analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID719473Antiviral activity against HCV subtype 1b infected in human hepatoma cells2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
ISSN: 1464-3405		Synthesis and antiviral activity of novel HCV NS3 protease inhibitors with P4 capping groups.
AID538712AUC (0 to infinity) in Sprague-Dawley rat at 5 mg/kg, po2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
ISSN: 1464-3405		Synthesis of new acylsulfamoyl benzoxaboroles as potent inhibitors of HCV NS3 protease.
AID1645923Inhibition of HCV NS3/4a protease using Ac-DE-Dap(QXL520)-EE-Abu-shi-[COO]AS-C(5-FAMsp)-NH2 as substrate after 15 mins2019European journal of medicinal chemistry, Feb-15, Volume: 164ISSN: 1768-3254A review on HCV inhibitors: Significance of non-structural polyproteins.
AID719467Antiviral activity against HCV subtype 1b expressing NS3/4A D168V mutant protease infected in ET cells after 72 hrs2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
ISSN: 1464-3405		Synthesis and antiviral activity of novel HCV NS3 protease inhibitors with P4 capping groups.
AID711493Ratio of drug level in liver to plasma of rat2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
ISSN: 1520-4804		Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.
AID1070628Oral bioavailability in monkey liver2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID664159Antiviral activity against Hepatitis C virus subtype 1b by stable replicon assay2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
ISSN: 1520-4804		Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
AID1698009Hepatic clearance in cynomolgus monkey at < 1 mg/kg, iv administered as cassette dosing2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
ISSN: 1520-4804
AID1070623Lipophilicity, log D of the compound2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID1070604Antiviral activity against Hepatitis C virus harboring wild type NS3/4A protease infected in human HuH7 cells assessed as inhibition of HCV subgenomic replicon replication after 72 hrs by ELISA2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID656675Antiviral activity against Hepatitis C virus genotype 1b expressing NS3/4A protease D158V mutant infected in HuH7 cells2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
ISSN: 1464-3405		Discovery of novel P3-oxo inhibitor of hepatitis C virus NS3/4A serine protease.
AID521271Selectivity ratio of EC50 for Hepatitis C virus genotype 1b N expressing NS3 R155K mutant infected in human HuH7 cells to EC50 for Hepatitis C virus genotype 1b N expressing wild type NS3 infected in human HuH7 cells2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
ISSN: 0066-4804		Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID584104Ratio of EC50 for wild type HCV1b harboring NS3 protease gene to EC50 for HCV1b B10 harboring NS3 protease S7A, R26K, V48I, T54S mutant2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
ISSN: 1098-6596		Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors.
AID1070629Oral bioavailability in rat liver2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID1070618Aqueous solubility of the compound at pH 1.2 by modified shake-flask method2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID1070650Antiviral activity against Hepatitis C virus infected in human HuH7 cells assessed as inhibition of HCV subgenomic replicon replication after 72 hrs by ELISA2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID521275Selectivity ratio of EC50 for Hepatitis C virus genotype 1b N expressing NS3 T54A mutant infected in human HuH7 cells to EC50 for Hepatitis C virus genotype 1b N expressing wild type NS3 infected in human HuH7 cells2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
ISSN: 0066-4804		Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID656672Antiviral activity against Hepatitis C virus genotype 1b expressing NS3/4A protease A156T mutant infected in HuH7 cells2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
ISSN: 1464-3405		Discovery of novel P3-oxo inhibitor of hepatitis C virus NS3/4A serine protease.
AID1071911Inhibition of Hepatitis C virus genotype 1b NS3 protease domain assessed as overall/observed affinity by surface plasmon resonance biosensor-based interaction kinetic analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID539675Oral bioavailability in rat2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
ISSN: 1464-3405		Synthesis and biological evaluations of P4-benzoxaborole-substituted macrocyclic inhibitors of HCV NS3 protease.
AID1698004Fraction unbound in cynomolgus monkey plasma2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
ISSN: 1520-4804
AID1070620Metabolic stability in cynomolgus monkey hepatocytes assessed as extraction ratio at 1 uM2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID1071910Inhibition of Hepatitis C virus genotype 3a full-length NS3 protease assessed as overall/observed affinity by surface plasmon resonance biosensor-based interaction kinetic analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
ISSN: 1520-4804		Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID521278Antiviral activity against Hepatitis C virus genotype 1b N expressing NS3 A156S mutant infected in human HuH7 cells2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
ISSN: 0066-4804		Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID521272Selectivity ratio of EC50 for Hepatitis C virus genotype 1b N expressing NS3 R155Q mutant infected in human HuH7 cells to EC50 for Hepatitis C virus genotype 1b N expressing wild type NS3 infected in human HuH7 cells2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
ISSN: 0066-4804		Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
ISSN: 1754-8411		In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
ISSN: 1754-8411		In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.

Research

Studies (76)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (2.63)29.6817
2010's63 (82.89)24.3611
2020's11 (14.47)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials30 (37.50%)5.53%
Reviews6 (7.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational2 (2.50%)0.25%
Other42 (52.50%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
aminolevulinic acid
1
4-oxo monocarboxylic acid;
amino acid zwitterion;
delta-amino acid		antineoplastic agent;
dermatologic drug;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
photosensitizing agent;
plant metabolite;
prodrug;
Saccharomyces cerevisiae metabolite		202320231.0low000001
coumarin
1
coumarinsfluorescent dye;
human metabolite;
plant metabolite		202320231.0low000001
salicylic acid
1
monohydroxybenzoic acidalgal metabolite;
antifungal agent;
antiinfective agent;
EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor;
keratolytic drug;
plant hormone;
plant metabolite		202320231.0low000001
thioctic acid
1
dithiolanes;
heterocyclic fatty acid;
thia fatty acid		fundamental metabolite;
geroprotector		202320231.0low000001
picolinic acid
1
pyridinemonocarboxylic acidhuman metabolite;
MALDI matrix material		202320231.0low000001
thiamine
1
primary alcohol;
vitamin B1		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		202320231.0low000001
3-aminobenzamide
1
benzamides;
substituted aniline		EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor202320231.0low000001
pleconaril
1
202320231.0low000001
4-(2-aminoethyl)benzenesulfonylfluoride
1
202320231.0low000001
phenytoin
1
imidazolidine-2,4-dioneanticonvulsant;
drug allergen;
sodium channel blocker;
teratogenic agent		202320231.0low000001
acetazolamide
1
monocarboxylic acid amide;
sulfonamide;
thiadiazoles		anticonvulsant;
diuretic;
EC 4.2.1.1 (carbonic anhydrase) inhibitor		202320231.0low000001
alprenolol
1
secondary alcohol;
secondary amino compound		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent		202320231.0low000001
amantadine
1
adamantanes;
primary aliphatic amine		analgesic;
antiparkinson drug;
antiviral drug;
dopaminergic agent;
NMDA receptor antagonist;
non-narcotic analgesic		202320231.0low000001
2-aminothiazole
1
1,3-thiazoles;
primary amino compound		202320231.0low000001
amodiaquine
1
aminoquinoline;
organochlorine compound;
phenols;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
drug allergen;
EC 2.1.1.8 (histamine N-methyltransferase) inhibitor;
non-steroidal anti-inflammatory drug;
prodrug		202320231.0low000001
aspirin
1
benzoic acids;
phenyl acetates;
salicylates		anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent		202320231.0low000001
baclofen
1
amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid;
monochlorobenzenes;
primary amino compound		central nervous system depressant;
GABA agonist;
muscle relaxant		202320231.0low000001
benzamide
1
benzamides202320231.0low000001
camostat
1
benzoate ester;
carboxylic ester;
diester;
guanidines;
tertiary carboxamide		anti-inflammatory agent;
anticoronaviral agent;
antifibrinolytic drug;
antihypertensive agent;
antineoplastic agent;
antiviral agent;
serine protease inhibitor		202320231.0low000001
camphor, (+-)-isomer
1
bornane monoterpenoid;
cyclic monoterpene ketone		plant metabolite202320231.0low000001
candesartan
1
benzimidazolecarboxylic acid;
biphenylyltetrazole		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic		202320231.0low000001
cetylpyridinium
1
pyridinium ion202320231.0low000001
chloroxylenol
1
monochlorobenzenes;
phenols		antiseptic drug;
disinfectant;
molluscicide		202320231.0low000001
chlorpromazine
1
organochlorine compound;
phenothiazines;
tertiary amine		anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
phenothiazine antipsychotic drug		202320231.0low000001
ciprofibrate
1
cyclopropanes;
monocarboxylic acid;
organochlorine compound		antilipemic drug202320231.0low000001
clomipramine
1
dibenzoazepineanticoronaviral agent;
antidepressant;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
serotonergic antagonist;
serotonergic drug;
serotonin uptake inhibitor		202320231.0low000001
danthron
1
dihydroxyanthraquinoneapoptosis inducer;
plant metabolite		202320231.0low000001
deferiprone
1
4-pyridonesiron chelator;
protective agent		202320231.0low000001
dipyridamole
1
piperidines;
pyrimidopyrimidine;
tertiary amino compound;
tetrol		adenosine phosphodiesterase inhibitor;
EC 3.5.4.4 (adenosine deaminase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent		202320231.0low000001
disulfiram
1
organic disulfide;
organosulfur acaricide		angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor;
EC 3.1.1.1 (carboxylesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
ferroptosis inducer;
fungicide;
NF-kappaB inhibitor		202320231.0low000001
valproic acid
1
branched-chain fatty acid;
branched-chain saturated fatty acid		anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent		202320231.0low000001
doxazosin
1
aromatic amine;
benzodioxine;
monocarboxylic acid amide;
N-acylpiperazine;
N-arylpiperazine;
quinazolines		alpha-adrenergic antagonist;
antihyperplasia drug;
antihypertensive agent;
antineoplastic agent;
vasodilator agent		202320231.0low000001
ebselen
1
benzoselenazoleanti-inflammatory drug;
antibacterial agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
EC 3.1.3.25 (inositol-phosphate phosphatase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
EC 3.5.4.1 (cytosine deaminase) inhibitor;
EC 5.1.3.2 (UDP-glucose 4-epimerase) inhibitor;
enzyme mimic;
ferroptosis inhibitor;
genotoxin;
hepatoprotective agent;
neuroprotective agent;
radical scavenger		202320231.0low000001
etidronate
1
1,1-bis(phosphonic acid)antineoplastic agent;
bone density conservation agent;
chelator		202320231.0low000001
2-hexyloxybenzamide
1
aromatic ether;
benzamides		antifungal agent202320231.0low000001
brl 42810
1
2-aminopurines;
acetate ester		antiviral drug;
prodrug		202320231.0low000001
fluphenazine
1
N-alkylpiperazine;
organofluorine compound;
phenothiazines		anticoronaviral agent;
dopaminergic antagonist;
phenothiazine antipsychotic drug		202320231.0low000001
fluorouracil
1
nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic		202320231.0low000001
gabexate
1
benzoate ester202320231.0low000001
glutaral
1
dialdehydecross-linking reagent;
disinfectant;
fixative		202320231.0low000001
fasudil
1
isoquinolines;
N-sulfonyldiazepane		antihypertensive agent;
calcium channel blocker;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
geroprotector;
neuroprotective agent;
nootropic agent;
vasodilator agent		202320231.0low000001
haloperidol
1
aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol		antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist		202320231.0low000001
miltefosine
1
phosphocholines;
phospholipid		anti-inflammatory agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antiprotozoal drug;
apoptosis inducer;
immunomodulator;
protein kinase inhibitor		202320231.0low000001
hexylresorcinol
1
resorcinols202320231.0low000001
beta-thujaplicin
1
cyclic ketone;
enol;
monoterpenoid		antibacterial agent;
antifungal agent;
antineoplastic agent;
antiplasmodial drug;
plant metabolite		202320231.0low000001
hycanthone
1
thioxanthenesmutagen;
schistosomicide drug		202320231.0low000001
hydrochlorothiazide
1
benzothiadiazine;
organochlorine compound;
sulfonamide		antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic		202320231.0low000001
hydroxyurea
1
one-carbon compound;
ureas		antimetabolite;
antimitotic;
antineoplastic agent;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
genotoxin;
immunomodulator;
radical scavenger;
teratogenic agent		202320231.0low000001
ibuprofen
1
monocarboxylic acidantipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
radical scavenger;
xenobiotic		202320231.0low000001
indomethacin
1
aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic		202320231.0low000001
avapro
1
azaspiro compound;
biphenylyltetrazole		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic		202320231.0low000001
itraconazole
1
piperazines202320231.0low000001
kojic acid
1
4-pyranones;
enol;
primary alcohol		Aspergillus metabolite;
EC 1.10.3.1 (catechol oxidase) inhibitor;
EC 1.10.3.2 (laccase) inhibitor;
EC 1.13.11.24 (quercetin 2,3-dioxygenase) inhibitor;
EC 1.14.18.1 (tyrosinase) inhibitor;
EC 1.4.3.3 (D-amino-acid oxidase) inhibitor;
NF-kappaB inhibitor;
skin lightening agent		202320231.0low000001
lapachol
1
202320231.0low000001
loperamide
1
monocarboxylic acid amide;
monochlorobenzenes;
piperidines;
tertiary alcohol		anticoronaviral agent;
antidiarrhoeal drug;
mu-opioid receptor agonist		202320231.0low000001
loratadine
1
benzocycloheptapyridine;
ethyl ester;
N-acylpiperidine;
organochlorine compound;
tertiary carboxamide		anti-allergic agent;
cholinergic antagonist;
geroprotector;
H1-receptor antagonist		202320231.0low000001
losartan
1
biphenylyltetrazole;
imidazoles		angiotensin receptor antagonist;
anti-arrhythmia drug;
antihypertensive agent;
endothelin receptor antagonist		202320231.0low000001
4-(dimethylamino)-n-(7-(hydroxyamino)-7-oxoheptyl)benzamide
1
benzamides;
hydroxamic acid;
secondary carboxamide;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor		202320231.0low000001
mafenide
1
aromatic amine202320231.0low000001
methazolamide
1
sulfonamide;
thiadiazoles		202320231.0low000001
methocarbamol
1
aromatic ether;
carbamate ester;
secondary alcohol		202320231.0low000001
mitoxantrone
1
dihydroxyanthraquinoneanalgesic;
antineoplastic agent		202320231.0low000001
entinostat
1
benzamides;
carbamate ester;
primary amino compound;
pyridines;
substituted aniline		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor		202320231.0low000001
ethylmaleimide
1
maleimidesanticoronaviral agent;
EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor;
EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor;
EC 2.7.1.1 (hexokinase) inhibitor		202320231.0low000001
nabumetone
1
methoxynaphthalene;
methyl ketone		cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug		202320231.0low000001
nafamostat
1
benzoic acids;
guanidines		202320231.0low000001
nevirapine
1
cyclopropanes;
dipyridodiazepine		antiviral drug;
HIV-1 reverse transcriptase inhibitor		202320231.0low000001
omeprazole
1
aromatic ether;
benzimidazoles;
pyridines;
sulfoxide		202320231.0low000001
osalmide
1
organic molecular entity202320231.0low000001
oxethazaine
1
amino acid amide202320231.0low000001
palmidrol
1
endocannabinoid;
N-(long-chain-acyl)ethanolamine;
N-(saturated fatty acyl)ethanolamine		anti-inflammatory drug;
anticonvulsant;
antihypertensive agent;
neuroprotective agent		202320231.0low000001
papaverine
1
benzylisoquinoline alkaloid;
dimethoxybenzene;
isoquinolines		antispasmodic drug;
vasodilator agent		202320231.0low000001
pentoxifylline
1
oxopurine202320231.0low000001
perhexiline
1
piperidinescardiovascular drug202320231.0low000001
phenazopyridine
1
diaminopyridine;
monoazo compound		anticoronaviral agent;
carcinogenic agent;
local anaesthetic;
non-narcotic analgesic		202320231.0low000001
4-phenylbutyric acid
1
monocarboxylic acidantineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor;
prodrug		202320231.0low000001
phenylmethylsulfonyl fluoride
1
acyl fluorideserine proteinase inhibitor202320231.0low000001
pimobendan
1
benzimidazoles;
pyridazinone		cardiotonic drug;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent		202320231.0low000001
pj-34
1
phenanthridines;
secondary carboxamide;
tertiary amino compound		angiogenesis inhibitor;
anti-inflammatory agent;
antiatherosclerotic agent;
antineoplastic agent;
apoptosis inducer;
cardioprotective agent;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
neuroprotective agent		202320231.0low000001
praziquantel
1
isoquinolines202320231.0low000001
probenecid
1
benzoic acids;
sulfonamide		uricosuric drug202320231.0low000001
probucol
1
dithioketal;
polyphenol		anti-inflammatory drug;
anticholesteremic drug;
antilipemic drug;
antioxidant;
cardiovascular drug		202320231.0low000001
promazine
1
phenothiazines;
tertiary amine		antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
muscarinic antagonist;
phenothiazine antipsychotic drug;
serotonergic antagonist		202320231.0low000001
promethazine
1
phenothiazines;
tertiary amine		anti-allergic agent;
anticoronaviral agent;
antiemetic;
antipruritic drug;
H1-receptor antagonist;
local anaesthetic;
sedative		202320231.0low000001
propranolol
1
naphthalenes;
propanolamine;
secondary amine		anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic		202320231.0low000001
rimantadine
1
alkylamine202320231.0low000001
rolipram
1
pyrrolidin-2-onesantidepressant;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor		202320231.0low000001
scriptaid
1
isoquinolines202320231.0low000001
sebacic acid
1
alpha,omega-dicarboxylic acid;
dicarboxylic fatty acid		human metabolite;
plant metabolite		202320231.0low000001
fenofibrate
1
benzochromenone;
delta-lactone;
naphtho-alpha-pyrone		platelet aggregation inhibitor;
Sir2 inhibitor		202320231.0low000001
imatinib
1
aromatic amine;
benzamides;
N-methylpiperazine;
pyridines;
pyrimidines		antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor		202320231.0low000001
suprofen
1
aromatic ketone;
monocarboxylic acid;
thiophenes		antirheumatic drug;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug		202320231.0low000001
thalidomide
1
phthalimides;
piperidones		202320231.0low000001
ticlopidine
1
monochlorobenzenes;
thienopyridine		anticoagulant;
fibrin modulating drug;
hematologic agent;
P2Y12 receptor antagonist;
platelet aggregation inhibitor		202320231.0low000001
triamterene
1
pteridinesdiuretic;
sodium channel blocker		202320231.0low000001
trifluoperazine
1
N-alkylpiperazine;
N-methylpiperazine;
organofluorine compound;
phenothiazines		antiemetic;
calmodulin antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor;
phenothiazine antipsychotic drug		202320231.0low000001
triflupromazine
1
organofluorine compound;
phenothiazines;
tertiary amine		anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic		202320231.0low000001
trigonelline
1
alkaloid;
iminium betaine		food component;
human urinary metabolite;
plant metabolite		202320231.0low000001
trimethobenzamide
1
benzamides;
tertiary amino compound		antiemetic202320231.0low000001
trimethoprim
1
aminopyrimidine;
methoxybenzenes		antibacterial drug;
diuretic;
drug allergen;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
environmental contaminant;
xenobiotic		202320231.0low000001
tyrphostin a9
1
alkylbenzenegeroprotector202320231.0low000001
delavirdine
1
aminopyridine;
indolecarboxamide;
N-acylpiperazine;
sulfonamide		antiviral drug;
HIV-1 reverse transcriptase inhibitor		202320231.0low000001
vesnarinone
1
organic molecular entity202320231.0low000001
idoxuridine
1
organoiodine compound;
pyrimidine 2'-deoxyribonucleoside		antiviral drug;
DNA synthesis inhibitor		202320231.0low000001
chloramphenicol
1
C-nitro compound;
carboxamide;
diol;
organochlorine compound		antibacterial drug;
antimicrobial agent;
Escherichia coli metabolite;
geroprotector;
Mycoplasma genitalium metabolite;
protein synthesis inhibitor		202320231.0low000001
lysine
1
aspartate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
lysine;
organic molecular entity;
proteinogenic amino acid		algal metabolite;
anticonvulsant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite		202320231.0low000001
phenylethyl alcohol
1
benzenes;
primary alcohol		Aspergillus metabolite;
fragrance;
plant growth retardant;
plant metabolite;
Saccharomyces cerevisiae metabolite		202320231.0low000001
zoxazolamine
1
benzoxazole202320231.0low000001
cycloheximide
1
antibiotic fungicide;
cyclic ketone;
dicarboximide;
piperidine antibiotic;
piperidones;
secondary alcohol		anticoronaviral agent;
bacterial metabolite;
ferroptosis inhibitor;
neuroprotective agent;
protein synthesis inhibitor		202320231.0low000001
ficusin
1
psoralensplant metabolite202320231.0low000001
tubercidin
1
antibiotic antifungal agent;
N-glycosylpyrrolopyrimidine;
ribonucleoside		antimetabolite;
antineoplastic agent;
bacterial metabolite		202320231.0low000001
trifluridine
1
nucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
EC 2.1.1.45 (thymidylate synthase) inhibitor		202320231.0low000001
9,10-anthraquinone
1
anthraquinone202320231.0low000001
salicylanilide
1
benzanilide fungicide;
salicylamides;
salicylanilides		202320231.0low000001
gramine
1
aminoalkylindole;
indole alkaloid;
tertiary amino compound		antibacterial agent;
antiviral agent;
plant metabolite;
serotonergic antagonist		202320231.0low000001
aminacrine
1
aminoacridines;
primary amino compound		acid-base indicator;
antiinfective agent;
antiseptic drug;
fluorescent dye;
MALDI matrix material;
mutagen		202320231.0low000001
methyl gallate
1
gallate esteranti-inflammatory agent;
antioxidant;
plant metabolite		202320231.0low000001
monobenzone
1
benzyl etherallergen;
dermatologic drug;
melanin synthesis inhibitor		202320231.0low000001
ditiocarb
1
dithiocarbamic acidschelator;
copper chelator		202320231.0low000001
catechin
1
catechinantioxidant;
plant metabolite		202320231.0low000001
azacitidine
1
N-glycosyl-1,3,5-triazine;
nucleoside analogue		antineoplastic agent202320231.0low000001
lucanthone
1
thioxanthenesadjuvant;
antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
mutagen;
photosensitizing agent;
prodrug;
schistosomicide drug		202320231.0low000001
cepharanthine
1
bisbenzylisoquinoline alkaloid;
isoquinolines		202320231.0low000001
aloe emodin
1
aromatic primary alcohol;
dihydroxyanthraquinone		antineoplastic agent;
plant metabolite		202320231.0low000001
chrysophanic acid
1
dihydroxyanthraquinoneanti-inflammatory agent;
antiviral agent;
plant metabolite		202320231.0low000001
emetine
1
isoquinoline alkaloid;
pyridoisoquinoline		antiamoebic agent;
anticoronaviral agent;
antiinfective agent;
antimalarial;
antineoplastic agent;
antiprotozoal drug;
antiviral agent;
autophagy inhibitor;
emetic;
expectorant;
plant metabolite;
protein synthesis inhibitor		202320231.0low000001
osthol
1
botanical anti-fungal agent;
coumarins		metabolite202320231.0low000001
flavanone
1
flavanones202320231.0low000001
phloretic acid
1
hydroxy monocarboxylic acidplant metabolite202320231.0low000001
oleanolic acid
1
hydroxy monocarboxylic acid;
pentacyclic triterpenoid		plant metabolite202320231.0low000001
angelicin
1
furanocoumarin202320231.0low000001
diperodon
1
carbamate ester202320231.0low000001
megestrol acetate
1
20-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
steroid ester		antineoplastic agent;
appetite enhancer;
contraceptive drug;
progestin;
synthetic oral contraceptive		202320231.0low000001
acetylcysteine
1
acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid		antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary		202320231.0low000001
hydroxychloroquine sulfate
1
202320231.0low000001
ethambutol
1
ethanolamines;
ethylenediamine derivative		antitubercular agent;
environmental contaminant;
xenobiotic		202320231.0low000001
metformin hydrochloride
1
hydrochlorideenvironmental contaminant;
hypoglycemic agent;
xenobiotic		202320231.0low000001
antimycin a
1
benzamides;
formamides;
macrodiolide;
phenols		antifungal agent;
mitochondrial respiratory-chain inhibitor;
piscicide		202320231.0low000001
5,5'-dimethyl-2,2'-bipyridyl
1
bipyridines202320231.0medium000001
dichlorobenzyl alcohol
1
benzyl alcohols;
dichlorobenzene		antiseptic drug202320231.0low000001
stavudine
1
dihydrofuran;
nucleoside analogue;
organic molecular entity		antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor		202320231.0low000001
dideoxyadenosine
1
adenosines;
purine 2',3'-dideoxyribonucleoside		EC 3.5.4.4 (adenosine deaminase) inhibitor;
EC 4.6.1.1 (adenylate cyclase) inhibitor		202320231.0low000001
vidarabine
1
beta-D-arabinoside;
purine nucleoside		antineoplastic agent;
bacterial metabolite;
nucleoside antibiotic		202320231.0low000001
3-deazaadenosine
1
202320231.0low000001
zalcitabine
1
pyrimidine 2',3'-dideoxyribonucleosideantimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor		202320231.0low000001
ancitabine
1
diol;
organic heterotricyclic compound		antimetabolite;
antineoplastic agent;
prodrug		202320231.0low000001
chloropyramine
1
aminopyridine202320231.0low000001
levamisole
1
6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazoleantinematodal drug;
antirheumatic drug;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
immunological adjuvant;
immunomodulator		202320231.0low000001
n'-nitrosonornicotine
1
pyridines;
pyrrolidines		202320231.0low000001
daunorubicin
1
aminoglycoside antibiotic;
anthracycline;
p-quinones;
tetracenequinones		antineoplastic agent;
bacterial metabolite		202320231.0low000001
zidovudine
1
azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor		202320231.0low000001
ribavirin
1
1-ribosyltriazole;
aromatic amide;
monocarboxylic acid amide;
primary carboxamide		anticoronaviral agent;
antiinfective agent;
antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor		202320231.0low000001
pyridoxal phosphate
1
pyridinecarbaldehyde202320231.0medium000001
nitazoxanide
1
benzamides;
carboxylic ester		202320231.0low000001
captopril
1
alkanethiol;
L-proline derivative;
N-acylpyrrolidine;
pyrrolidinemonocarboxylic acid		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor		202320231.0low000001
oltipraz
1
1,2-dithiole;
pyrazines		angiogenesis modulating agent;
antimutagen;
antineoplastic agent;
antioxidant;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
neurotoxin;
protective agent;
schistosomicide drug		202320231.0low000001
fiacitabine
1
202320231.0low000001
ranolazine
1
aromatic amide;
monocarboxylic acid amide;
monomethoxybenzene;
N-alkylpiperazine;
secondary alcohol		202320231.0low000001
brequinar
1
biphenyls;
monocarboxylic acid;
monofluorobenzenes;
quinolinemonocarboxylic acid		anticoronaviral agent;
antimetabolite;
antineoplastic agent;
antiviral agent;
EC 1.3.5.2 [dihydroorotate dehydrogenase (quinone)] inhibitor;
immunosuppressive agent;
pyrimidine synthesis inhibitor		202320231.0low000001
imiquimod
2
imidazoquinolineantineoplastic agent;
interferon inducer		201920233.0low000011
adefovir
1
6-aminopurines;
ether;
phosphonic acids		antiviral drug;
DNA synthesis inhibitor;
drug metabolite;
HIV-1 reverse transcriptase inhibitor;
nephrotoxic agent		202320231.0low000001
cidofovir anhydrous
1
phosphonic acids;
pyrimidone		anti-HIV agent;
antineoplastic agent;
antiviral drug;
photosensitizing agent		202320231.0low000001
celgosivir
1
202320231.0low000001
gemcitabine
1
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
environmental contaminant;
immunosuppressive agent;
photosensitizing agent;
prodrug;
radiosensitizing agent;
xenobiotic		202320231.0low000001
lamivudine
1
monothioacetal;
nucleoside analogue;
oxacycle;
primary alcohol		allergen;
anti-HBV agent;
antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor;
prodrug		202320231.0low000001
valsartan
1
biphenylyltetrazole;
monocarboxylic acid amide;
monocarboxylic acid		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic		202320231.0low000001
zanamivir
1
guanidinesantiviral agent;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor		202320231.0low000001
adefovir dipivoxil
1
6-aminopurines;
carbonate ester;
ether;
organic phosphonate		antiviral drug;
DNA synthesis inhibitor;
HIV-1 reverse transcriptase inhibitor;
nephrotoxic agent;
prodrug		202320231.0low000001
emtricitabine
1
monothioacetal;
nucleoside analogue;
organofluorine compound;
pyrimidone		antiviral drug;
HIV-1 reverse transcriptase inhibitor		202320231.0low000001
octyl gallate
1
gallate esterfood antioxidant;
hypoglycemic agent;
plant metabolite		202320231.0low000001
efavirenz
1
acetylenic compound;
benzoxazine;
cyclopropanes;
organochlorine compound;
organofluorine compound		antiviral drug;
HIV-1 reverse transcriptase inhibitor		202320231.0low000001
nelfinavir
1
aryl sulfide;
benzamides;
organic heterobicyclic compound;
phenols;
secondary alcohol;
tertiary amino compound		antineoplastic agent;
HIV protease inhibitor		202320231.0low000001
betulinic acid
1
hydroxy monocarboxylic acid;
pentacyclic triterpenoid		anti-HIV agent;
anti-inflammatory agent;
antimalarial;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
plant metabolite		202320231.0low000001
arctigenin
1
lignan202320231.0low000001
baicalin
1
dihydroxyflavone;
glucosiduronic acid;
glycosyloxyflavone;
monosaccharide derivative		antiatherosclerotic agent;
antibacterial agent;
anticoronaviral agent;
antineoplastic agent;
antioxidant;
cardioprotective agent;
EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
ferroptosis inhibitor;
neuroprotective agent;
non-steroidal anti-inflammatory drug;
plant metabolite;
prodrug		202320231.0low000001
plerixafor
1
azacycloalkane;
azamacrocycle;
benzenes;
crown amine;
secondary amino compound;
tertiary amino compound		anti-HIV agent;
antineoplastic agent;
C-X-C chemokine receptor type 4 antagonist;
immunological adjuvant		202320231.0low000001
amprenavir
1
carbamate ester;
sulfonamide;
tetrahydrofuryl ester		antiviral drug;
HIV protease inhibitor		202320231.0low000001
oseltamivir
1
acetamides;
amino acid ester;
cyclohexenecarboxylate ester;
primary amino compound		antiviral drug;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor;
environmental contaminant;
prodrug;
xenobiotic		202320231.0low000001
epigallocatechin gallate
1
flavans;
gallate ester;
polyphenol		antineoplastic agent;
antioxidant;
apoptosis inducer;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent;
plant metabolite		202320231.0low000001
1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose
1
gallate ester;
galloyl beta-D-glucose		anti-inflammatory agent;
antineoplastic agent;
geroprotector;
hepatoprotective agent;
plant metabolite;
radiation protective agent;
radical scavenger		202320231.0low000001
cephalotaxine
1
benzazepine alkaloid fundamental parent;
benzazepine alkaloid;
cyclic acetal;
enol ether;
organic heteropentacyclic compound;
secondary alcohol;
tertiary amino compound		202320231.0medium000001
desipramine hydrochloride
1
hydrochloridedrug allergen202320231.0low000001
mefloquine hydrochloride
1
hydrochloride202320231.0low000001
aloxistatin
1
epoxide;
ethyl ester;
L-leucine derivative;
monocarboxylic acid amide		anticoronaviral agent;
cathepsin B inhibitor		202320231.0low000001
propazole
1
benzimidazoles202320231.0low000001
prulifloxacin
1
fluoroquinolone antibiotic;
quinolone antibiotic		202320231.0low000001
telmisartan
1
benzimidazoles;
biphenyls;
carboxybiphenyl		angiotensin receptor antagonist;
antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
environmental contaminant;
xenobiotic		202320231.0low000001
bergenin
1
trihydroxybenzoic acidmetabolite202320231.0low000001
zoledronic acid
1
1,1-bis(phosphonic acid);
imidazoles		bone density conservation agent202320231.0low000001
artemisinin
1
organic peroxide;
sesquiterpene lactone		antimalarial;
plant metabolite		202320231.0low000001
brinzolamide
1
sulfonamide;
thienothiazine		antiglaucoma drug;
EC 4.2.1.1 (carbonic anhydrase) inhibitor		202320231.0low000001
dipropylacetamide
1
fatty amidegeroprotector;
metabolite;
teratogenic agent		202320231.0low000001
oxprenolol hydrochloride
1
202320231.0low000001
opipramol hydrochloride
1
202320231.0low000001
moroxydine
1
biguanides202320231.0low000001
thioxolone
1
benzoxathioleantiseborrheic202320231.0low000001
honokiol
1
biphenyls202320231.0low000001
nobiletin
1
methoxyflavoneantineoplastic agent;
plant metabolite		202320231.0low000001
lycorine
1
indolizidine alkaloidanticoronaviral agent;
antimalarial;
plant metabolite;
protein synthesis inhibitor		202320231.0low000001
leupeptin
1
aldehyde;
tripeptide		bacterial metabolite;
calpain inhibitor;
cathepsin B inhibitor;
EC 3.4.21.4 (trypsin) inhibitor;
serine protease inhibitor		202320231.0low000001
tetrandrine
1
bisbenzylisoquinoline alkaloid;
isoquinolines		202320231.0low000001
calpeptin
1
amino acid amide202320231.0low000001
fangchinoline
1
aromatic ether;
bisbenzylisoquinoline alkaloid;
macrocycle		anti-HIV-1 agent;
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
neuroprotective agent;
plant metabolite		202320231.0low000001
maslinic acid
1
dihydroxy monocarboxylic acid;
pentacyclic triterpenoid		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
plant metabolite		202320231.0low000001
atovaquone
1
hydroxy-1,2-naphthoquinone202320231.0low000001
loganin
1
beta-D-glucoside;
cyclopentapyran;
enoate ester;
iridoid monoterpenoid;
methyl ester;
monosaccharide derivative;
secondary alcohol		anti-inflammatory agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
EC 3.4.23.46 (memapsin 2) inhibitor;
neuroprotective agent;
plant metabolite		202320231.0low000001
moexipril
1
peptide202320231.0low000001
aucubin
1
organic molecular entitymetabolite202320231.0low000001
catalpol
1
organic molecular entitymetabolite202320231.0low000001
lekoptin
1
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile202320231.0low000001
n-methyladenosine
1
methyladenosine202320231.0low000001
sivelestat
1
N-acylglycine;
pivalate ester		202320231.0low000001
pyronaridine
1
aminoquinoline202320231.0low000001
geniposide
1
terpene glycoside202320231.0low000001
daidzin
1
7-hydroxyisoflavones 7-O-beta-D-glucoside;
hydroxyisoflavone;
monosaccharide derivative		plant metabolite202320231.0low000001
sophocarpine
1
202320231.0low000001
marimastat
1
hydroxamic acid;
secondary carboxamide		antineoplastic agent;
matrix metalloproteinase inhibitor		202320231.0low000001
elacridar
1
202320231.0low000001
celastrol
1
monocarboxylic acid;
pentacyclic triterpenoid		anti-inflammatory drug;
antineoplastic agent;
antioxidant;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
Hsp90 inhibitor;
metabolite		202320231.0low000001
n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine
1
leucine derivative202320231.0low000001
vadimezan
1
monocarboxylic acid;
xanthones		antineoplastic agent202320231.0low000001
e 64
1
dicarboxylic acid monoamide;
epoxy monocarboxylic acid;
guanidines;
L-leucine derivative;
zwitterion		antimalarial;
antiparasitic agent;
protease inhibitor		202320231.0low000001
umifenovir
1
indolyl carboxylic acid202320231.0low000001
safinamide
1
amino acid amide202320231.0low000001
ilomastat
1
hydroxamic acid;
L-tryptophan derivative;
N-acyl-amino acid		anti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
EC 3.4.24.24 (gelatinase A) inhibitor;
neuroprotective agent		202320231.0low000001
atazanavir
1
carbohydrazideantiviral drug;
HIV protease inhibitor		202320231.0low000001
vx 497
1
202320231.0low000001
bcx 1812
1
3-hydroxy monocarboxylic acid;
acetamides;
cyclopentanols;
guanidines		antiviral drug;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor		202320231.0low000001
naproxen
1
methoxynaphthalene;
monocarboxylic acid		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic		202320231.0low000001
olmesartan
1
biphenylyltetrazoleangiotensin receptor antagonist;
antihypertensive agent		202320231.0low000001
telbivudine
1
pyrimidine 2'-deoxyribonucleosideantiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor		202320231.0low000001
celastrol methyl ester
1
carboxylic ester202320231.0low000001
resiquimod
1
imidazoquinoline202320231.0low000001
tanshinone ii a
1
abietane diterpenoid202320231.0low000001
anacardic acid
1
hydroxy monocarboxylic acid;
hydroxybenzoic acid		anti-inflammatory agent;
antibacterial agent;
anticoronaviral agent;
apoptosis inducer;
EC 2.3.1.48 (histone acetyltransferase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
neuroprotective agent;
plant metabolite		202320231.0low000001
migalastat
1
piperidines202320231.0low000001
erlotinib
1
aromatic ether;
quinazolines;
secondary amino compound;
terminal acetylenic compound		antineoplastic agent;
epidermal growth factor receptor antagonist;
protein kinase inhibitor		202320231.0low000001
limonin
1
epoxide;
furans;
hexacyclic triterpenoid;
lactone;
limonoid;
organic heterohexacyclic compound		inhibitor;
metabolite;
volatile oil component		202320231.0low000001
scutellarin
1
glucosiduronic acid;
glycosyloxyflavone;
monosaccharide derivative;
trihydroxyflavone		antineoplastic agent;
proteasome inhibitor		202320231.0low000001
etravirine
1
aminopyrimidine;
aromatic ether;
dinitrile;
organobromine compound		antiviral agent;
HIV-1 reverse transcriptase inhibitor		202320231.0low000001
chelidonine
1
alkaloid antibiotic;
alkaloid fundamental parent;
benzophenanthridine alkaloid		202320231.0low000001
4-n-butylresorcinol
1
resorcinols202320231.0low000001
darunavir
2
carbamate ester;
furofuran;
sulfonamide		antiviral drug;
HIV protease inhibitor		201120237.0low000011
dapivirine
1
202320231.0low000001
nsc 74859
1
amidobenzoic acid;
monohydroxybenzoic acid;
tosylate ester		STAT3 inhibitor202320231.0low000001
berbamine
1
bisbenzylisoquinoline alkaloid;
isoquinolines		202320231.0low000001
u-104
1
202320231.0low000001
7-hydroxy-5-methyl-2-(2-oxopropyl)-8-[3,4,5-trihydroxy-6-(hydroxymethyl)-2-oxanyl]-1-benzopyran-4-one
1
glycoside202320231.0medium000001
bortezomib
1
amino acid amide;
L-phenylalanine derivative;
pyrazines		antineoplastic agent;
antiprotozoal drug;
protease inhibitor;
proteasome inhibitor		202320231.0low000001
ritonavir
1
1,3-thiazoles;
carbamate ester;
carboxamide;
L-valine derivative;
ureas		antiviral drug;
environmental contaminant;
HIV protease inhibitor;
xenobiotic		202320231.0low000001
tizoxanide
1
salicylamides202320231.0low000001
arbutin
1
beta-D-glucoside;
monosaccharide derivative		Escherichia coli metabolite;
plant metabolite		202320231.0low000001
quinidine
1
cinchona alkaloidalpha-adrenergic antagonist;
anti-arrhythmia drug;
antimalarial;
drug allergen;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
muscarinic antagonist;
P450 inhibitor;
potassium channel blocker;
sodium channel blocker		202320231.0low000001
conessine
1
steroid alkaloid;
tertiary amino compound		antibacterial agent;
antimalarial;
H3-receptor antagonist;
plant metabolite		202320231.0low000001
saquinavir
1
L-asparagine derivative;
quinolines		antiviral drug;
HIV protease inhibitor		202320231.0low000001
abacavir
1
2,6-diaminopurinesantiviral drug;
drug allergen;
HIV-1 reverse transcriptase inhibitor		202320231.0low000001
linezolid
1
acetamides;
morpholines;
organofluorine compound;
oxazolidinone		antibacterial drug;
protein synthesis inhibitor		202320231.0low000001
cephaelin
1
pyridoisoquinoline202320231.0low000001
(-)-usnic acid
1
usnic acidEC 1.13.11.27 (4-hydroxyphenylpyruvate dioxygenase) inhibitor202320231.0medium000001
acetylleucyl-leucyl-norleucinal
1
aldehyde;
tripeptide		cysteine protease inhibitor202320231.0low000001
resveratrol
1
resveratrolantioxidant;
phytoalexin;
plant metabolite;
quorum sensing inhibitor;
radical scavenger		202320231.0low000001
tacrolimus
1
macrolide lactambacterial metabolite;
immunosuppressive agent		202320231.0low000001
lycopene
1
acyclic caroteneantioxidant;
plant metabolite		202320231.0low000001
zithromax
1
macrolide antibioticantibacterial drug;
environmental contaminant;
xenobiotic		202320231.0low000001
roflumilast
1
aromatic ether;
benzamides;
chloropyridine;
cyclopropanes;
organofluorine compound		anti-asthmatic drug;
phosphodiesterase IV inhibitor		202320231.0low000001
L-cycloserine
1
4-amino-1,2-oxazolidin-3-oneanti-HIV agent;
anticonvulsant;
EC 2.3.1.50 (serine C-palmitoyltransferase) inhibitor		202320231.0low000001
h 89
1
N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide202320231.0low000001
bevirimat
1
dicarboxylic acid monoester;
monocarboxylic acid;
pentacyclic triterpenoid		HIV-1 maturation inhibitor;
metabolite		202320231.0low000001
benzyloxycarbonylleucyl-leucyl-leucine aldehyde
1
amino aldehyde;
carbamate ester;
tripeptide		proteasome inhibitor202320231.0low000001
tenofovir
1
nucleoside analogue;
phosphonic acids		antiviral drug;
drug metabolite;
HIV-1 reverse transcriptase inhibitor		202320231.0low000001
posaconazole
1
aromatic ether;
conazole antifungal drug;
N-arylpiperazine;
organofluorine compound;
oxolanes;
triazole antifungal drug;
triazoles		trypanocidal drug202320231.0low000001
gw 257406x
1
202320231.0low000001
shikonin
1
hydroxy-1,4-naphthoquinone202320231.0low000001
4,4-difluoro-N-[(1S)-3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]-1-cyclohexanecarboxamide
1
tropane alkaloid202320231.0medium000001
cmx 001
1
202320231.0low000001
amd 8664
2
201120237.0high000011
bay 41-4109
1
202320231.0low000001
bay 57-1293
1
202320231.0low000001
2'-c-methylcytidine
1
202320231.0low000001
isoxanthohumol
1
flavanones202320231.0low000001
4-(4-chloro-2-methylphenoxy)-n-hydroxybutanamide
1
aromatic ether202320231.0low000001
mecarbinate
1
202320231.0low000001
acetyl-aspartyl-glutamyl-valyl-aspartal
1
tetrapeptideprotease inhibitor202320231.0low000001
octotropine methylbromide
1
202320231.0low000001
mercaptopurine
1
aryl thiol;
purines;
thiocarbonyl compound		anticoronaviral agent;
antimetabolite;
antineoplastic agent		202320231.0low000001
jrf 12
1
202320231.0low000001
3,4'-dihydroxyflavone
1
202320231.0medium000001
3-(3,4-dimethoxyphenyl)propenoic acid
1
methoxycinnamic acid202320231.0low000001
isoferulic acid
1
ferulic acidsantioxidant;
biomarker;
metabolite		202320231.0low000001
cyclouridine
1
202320231.0medium000001
curcumin
1
aromatic ether;
beta-diketone;
diarylheptanoid;
enone;
polyphenol		anti-inflammatory agent;
antifungal agent;
antineoplastic agent;
biological pigment;
contraceptive drug;
dye;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
flavouring agent;
food colouring;
geroprotector;
hepatoprotective agent;
immunomodulator;
iron chelator;
ligand;
lipoxygenase inhibitor;
metabolite;
neuroprotective agent;
nutraceutical;
radical scavenger		202320231.0low000001
zucapsaicin
1
methoxybenzenes;
phenols		202320231.0low000001
nbd 556
1
202320231.0low000001
thioguanine anhydrous
1
2-aminopurinesanticoronaviral agent;
antimetabolite;
antineoplastic agent		202320231.0low000001
4,5,6,7-tetrachloroindan-1,3-dione
1
202320231.0high000001
srpin340
1
202320231.0low000001
pr-619
1
202320231.0medium000001
p5091
1
202320231.0low000001
trovirdine
1
202320231.0low000001
fti 277
1
202320231.0high000001
u 0126
1
aryl sulfide;
dinitrile;
enamine;
substituted aniline		antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
osteogenesis regulator;
vasoconstrictor agent		202320231.0low000001
vicriviroc
1
(trifluoromethyl)benzenes202320231.0low000001
telaprevir
9
cyclopentapyrrole;
cyclopropanes;
oligopeptide;
pyrazines		antiviral drug;
hepatitis C protease inhibitor;
peptidomimetic		2008202312.0low000441
orlistat
1
beta-lactone;
carboxylic ester;
formamides;
L-leucine derivative		anti-obesity agent;
bacterial metabolite;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor		202320231.0low000001
dasatinib
1
1,3-thiazoles;
aminopyrimidine;
monocarboxylic acid amide;
N-(2-hydroxyethyl)piperazine;
N-arylpiperazine;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor		202320231.0low000001
yya-021
1
202320231.0medium000001
sb 415286
1
C-nitro compound;
maleimides;
monochlorobenzenes;
phenols;
secondary amino compound;
substituted aniline		antioxidant;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
neuroprotective agent		202320231.0low000001
sitagliptin
1
triazolopyrazine;
trifluorobenzene		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
environmental contaminant;
hypoglycemic agent;
serine proteinase inhibitor;
xenobiotic		202320231.0low000001
tak-220
1
202320231.0medium000001
jtk-303
1
aromatic ether;
monochlorobenzenes;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone		HIV-1 integrase inhibitor202320231.0low000001
nbd 557
1
202320231.0medium000001
5'-o-caffeoylquinic acid
1
cinnamate ester;
cyclitol carboxylic acid		plant metabolite202320231.0medium000001
luteolin-7-glucoside
1
beta-D-glucoside;
glycosyloxyflavone;
monosaccharide derivative;
trihydroxyflavone		antioxidant;
plant metabolite		202320231.0low000001
cyclosporine
1
202320231.0low000001
harmine
1
harmala alkaloidanti-HIV agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
metabolite		202320231.0low000001
eprosartan
1
dicarboxylic acid;
imidazoles;
thiophenes		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic		202320231.0low000001
mycophenolate mofetil
1
carboxylic ester;
ether;
gamma-lactone;
phenols;
tertiary amino compound		anticoronaviral agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
immunosuppressive agent;
prodrug		202320231.0low000001
entacapone
1
2-nitrophenols;
catechols;
monocarboxylic acid amide;
nitrile		antidyskinesia agent;
antiparkinson drug;
central nervous system drug;
EC 2.1.1.6 (catechol O-methyltransferase) inhibitor		202320231.0low000001
amentoflavone
1
biflavonoid;
hydroxyflavone;
ring assembly		angiogenesis inhibitor;
antiviral agent;
cathepsin B inhibitor;
P450 inhibitor;
plant metabolite		202320231.0low000001
baicalein
1
trihydroxyflavoneangiogenesis inhibitor;
anti-inflammatory agent;
antibacterial agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
EC 4.1.1.17 (ornithine decarboxylase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hormone antagonist;
plant metabolite;
prostaglandin antagonist;
radical scavenger		202320231.0low000001
genkwanin
1
dihydroxyflavone;
monomethoxyflavone		metabolite202320231.0low000001
hyperoside
1
beta-D-galactoside;
monosaccharide derivative;
quercetin O-glycoside;
tetrahydroxyflavone		hepatoprotective agent;
plant metabolite		202320231.0low000001
mangostin
1
aromatic ether;
phenols;
xanthones		antimicrobial agent;
antineoplastic agent;
antioxidant;
plant metabolite		202320231.0low000001
3-methylquercetin
1
7-hydroxyflavonol;
monomethoxyflavone;
tetrahydroxyflavone		anticoagulant;
EC 1.14.18.1 (tyrosinase) inhibitor;
metabolite		202320231.0low000001
kaempferide
1
7-hydroxyflavonol;
monomethoxyflavone;
trihydroxyflavone		antihypertensive agent;
metabolite		202320231.0low000001
orientin
1
3'-hydroxyflavonoid;
C-glycosyl compound;
tetrahydroxyflavone		antioxidant;
metabolite		202320231.0low000001
scutellarein
1
tetrahydroxyflavonemetabolite202320231.0low000001
trans-2,3',4,5'-tetrahydroxystilbene
1
stilbenoid202320231.0low000001
polydatin
1
beta-D-glucoside;
monosaccharide derivative;
polyphenol;
stilbenoid		anti-arrhythmia drug;
antioxidant;
geroprotector;
hepatoprotective agent;
metabolite;
nephroprotective agent;
potassium channel modulator		202320231.0low000001
chicoric acid
1
organooxygen compoundgeroprotector;
HIV-1 integrase inhibitor		202320231.0low000001
acteoside
1
catechols;
cinnamate ester;
disaccharide derivative;
glycoside;
polyphenol		anti-inflammatory agent;
antibacterial agent;
antileishmanial agent;
neuroprotective agent;
plant metabolite		202320231.0low000001
dorzolamide
1
sulfonamide;
thiophenes		antiglaucoma drug;
antihypertensive agent;
EC 4.2.1.1 (carbonic anhydrase) inhibitor		202320231.0low000001
topiramate
1
cyclic ketal;
ketohexose derivative;
sulfamate ester		anticonvulsant;
sodium channel blocker		202320231.0low000001
cyclotheonamide a
1
2011201113.0medium000010
benzyloxycarbonyl-phe-ala-fluormethylketone
1
202320231.0high000001
n-(n-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester
1
carboxylic ester;
difluorobenzene;
dipeptide;
tert-butyl ester		EC 3.4.23.46 (memapsin 2) inhibitor202320231.0low000001
casticin
1
dihydroxyflavone;
tetramethoxyflavone		apoptosis inducer;
plant metabolite		202320231.0low000001
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one
1
dihydroxyflavone;
monomethoxyflavone		antineoplastic agent;
EC 1.14.13.39 (nitric oxide synthase) inhibitor		202320231.0low000001
(E)-2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucoside
1
beta-D-glucoside;
resorcinols;
stilbenoid		anti-inflammatory agent;
antioxidant;
apoptosis inhibitor;
cardioprotective agent;
cyclooxygenase 2 inhibitor;
platelet aggregation inhibitor		202320231.0low000001
tyrphostin ag 555
1
202320231.0low000001
pd 151746
1
202320231.0medium000001
lisinopril
1
dipeptideEC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor202320231.0low000001
verteporfin
1
202320231.0low000001
batimastat
1
hydroxamic acid;
L-phenylalanine derivative;
organic sulfide;
secondary carboxamide;
thiophenes;
triamide		angiogenesis inhibitor;
antineoplastic agent;
matrix metalloproteinase inhibitor		202320231.0low000001
indinavir sulfate
1
dicarboxylic acid diamide;
N-(2-hydroxyethyl)piperazine;
piperazinecarboxamide		HIV protease inhibitor202320231.0low000001
solanesol
1
nonaprenol;
primary alcohol		plant metabolite202320231.0low000001
pepstatin
1
pentapeptide;
secondary carboxamide		bacterial metabolite;
EC 3.4.23.* (aspartic endopeptidase) inhibitor		202320231.0low000001
l 685458
1
carbamate ester;
monocarboxylic acid amide;
peptide;
secondary alcohol		EC 3.4.23.46 (memapsin 2) inhibitor;
peptidomimetic		202320231.0low000001
bms 806
1
202320231.0low000001
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone
1
202320231.0medium000001
tulobuterol hydrochloride
1
organic molecular entity202320231.0low000001
salubrinal
1
aminal;
organochlorine compound;
quinolines;
secondary carboxamide;
thioureas		202320231.0low000001
germacrone
1
germacrane sesquiterpenoid;
olefinic compound		androgen antagonist;
anti-inflammatory agent;
antifeedant;
antifungal agent;
antimicrobial agent;
antineoplastic agent;
antioxidant;
antitussive;
antiviral agent;
apoptosis inducer;
autophagy inducer;
hepatoprotective agent;
insecticide;
neuroprotective agent;
plant metabolite;
volatile oil component		202320231.0low000001
(2e,4e,6e,10e)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid
1
202320231.0low000001
lithospermic acid
1
202320231.0medium000001
laq824
1
202320231.0low000001
ekb 569
1
aminoquinoline;
monocarboxylic acid amide;
monochlorobenzenes;
nitrile		protein kinase inhibitor202320231.0low000001
rilpivirine
1
aminopyrimidine;
nitrile		EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor		202320231.0low000001
(1Ar,7aS,10aS,10bS)-1a,5-dimethyl-8-methylidene-2,3,6,7,7a,8,10a,10b-octahydrooxireno[9,10]cyclodeca[1,2-b]furan-9(1aH)-one
1
germacranolide202320231.0medium000001
4,5-di-O-caffeoylquinic acid
1
quinic acid202320231.0low000001
indigo carmine
1
202320231.0low000001
artesunate
1
artemisinin derivative;
cyclic acetal;
dicarboxylic acid monoester;
hemisuccinate;
semisynthetic derivative;
sesquiterpenoid		antimalarial;
antineoplastic agent;
ferroptosis inducer		202320231.0low000001
(3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone
1
oligopeptide202320231.0low000001
vildagliptin
1
amino acid amide202320231.0low000001
belinostat
1
hydroxamic acid;
olefinic compound;
sulfonamide		antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor		202320231.0low000001
hdac-42
1
amidobenzoic acid202320231.0low000001
chlorhexidine
1
biguanides;
monochlorobenzenes		antibacterial agent;
antiinfective agent		202320231.0low000001
gs-7340
1
6-aminopurines;
ether;
isopropyl ester;
L-alanine derivative;
phosphoramidate ester		antiviral drug;
HIV-1 reverse transcriptase inhibitor;
prodrug		202320231.0low000001
iniparib
1
carbonyl compound;
organohalogen compound		202320231.0low000001
n-(2-amino-5-fluorobenzyl)-4-(n-(pyridine-3-acrylyl)aminomethyl)benzamide
1
202320231.0low000001
pri-2205
1
202320231.0low000001
mk 0752
1
202320231.0low000001
givinostat
1
carbamate ester202320231.0low000001
pd 144418
1
202320231.0medium000001
bicyclol
1
202320231.0low000001
midostaurin
1
benzamides;
gamma-lactam;
indolocarbazole;
organic heterooctacyclic compound		antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor		202320231.0low000001
ly 450139
1
peptide202320231.0low000001
biln 2061
8
2008201912.4medium000350
mocetinostat
1
aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline		antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent		202320231.0low000001
rivaroxaban
1
aromatic amide;
lactam;
monocarboxylic acid amide;
morpholines;
organochlorine compound;
oxazolidinone;
thiophenes		anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor		202320231.0low000001
sb 3ct compound
1
aromatic ether202320231.0low000001
ginsenoside rb1
1
ginsenoside;
glycoside;
tetracyclic triterpenoid		anti-inflammatory drug;
anti-obesity agent;
apoptosis inhibitor;
neuroprotective agent;
plant metabolite;
radical scavenger		202320231.0low000001
rucaparib
1
azepinoindole;
caprolactams;
organofluorine compound;
secondary amino compound		antineoplastic agent;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor		202320231.0low000001
6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-n-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6s)-
1
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound		202320231.0low000001
cetilistat
1
benzoxazine202320231.0low000001
ym 201636
1
aromatic amide202320231.0low000001
sm360320
1
201920195.0low000010
linagliptin
1
aminopiperidine;
quinazolines		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent		202320231.0low000001
azd 6244
1
benzimidazoles;
bromobenzenes;
hydroxamic acid ester;
monochlorobenzenes;
organofluorine compound;
secondary amino compound		anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor		202320231.0low000001
odanacatib
1
202320231.0low000001
apilimod
1
202320231.0low000001
apixaban
1
aromatic ether;
lactam;
piperidones;
pyrazolopyridine		anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor		202320231.0low000001
betrixaban
1
benzamides;
guanidines;
monochloropyridine;
monomethoxybenzene;
secondary carboxamide		anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor		202320231.0low000001
edoxaban
1
chloropyridine;
monocarboxylic acid amide;
tertiary amino compound;
thiazolopyridine		anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor;
platelet aggregation inhibitor		202320231.0low000001
saracatinib
1
aromatic ether;
benzodioxoles;
diether;
N-methylpiperazine;
organochlorine compound;
oxanes;
quinazolines;
secondary amino compound		anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
radiosensitizing agent		202320231.0low000001
n-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
7
tripeptide;
ureas		antiviral drug;
hepatitis C protease inhibitor;
peptidomimetic		2008202311.4medium000331
ly 411575
1
dibenzoazepine;
difluorobenzene;
lactam;
secondary alcohol		EC 3.4.23.46 (memapsin 2) inhibitor202320231.0low000001
galidesivir
1
202320231.0low000001
PB28
1
aromatic ether;
piperazines;
tetralins		anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
sigma-2 receptor agonist		202320231.0low000001
degrasyn
1
202320231.0low000001
epoxomicin
1
morpholines;
tripeptide		proteasome inhibitor202320231.0low000001
bms 477118
1
adamantanes;
azabicycloalkane;
monocarboxylic acid amide;
nitrile;
tertiary alcohol		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent		202320231.0low000001
pha 680632
1
202320231.0low000001
tmc 353121
1
202320231.0medium000001
amd 070
1
aminoquinoline202320231.0low000001
bms-626529
1
202320231.0low000001
bms-663068
1
202320231.0low000001
amenamevir
1
202320231.0low000001
vx 765
1
dipeptide202320231.0low000001
Dihydrotanshinone I
1
abietane diterpenoidanticoronaviral agent202320231.0low000001
alogliptin
1
nitrile;
piperidines;
primary amino compound;
pyrimidines		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent		202320231.0low000001
fr 180204
1
pyrazoles;
ring assembly		202320231.0low000001
ulimorelin
1
oligopeptide2011201113.0low000010
quisinostat
1
indoles202320231.0low000001
carfilzomib
1
epoxide;
morpholines;
tetrapeptide		antineoplastic agent;
proteasome inhibitor		202320231.0low000001
hcv 796
1
202320231.0low000001
resminostat
1
202320231.0low000001
zk 756326
1
aromatic ether202320231.0medium000001
balapiravir
1
202320231.0low000001
trametinib
1
acetamides;
aromatic amine;
cyclopropanes;
organofluorine compound;
organoiodine compound;
pyridopyrimidine;
ring assembly		anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector		202320231.0low000001
deoxyarbutin
1
202320231.0low000001
abexinostat
1
benzofurans202320231.0low000001
silvestrol
1
dioxanes;
ether;
methyl ester;
organic heterotricyclic compound		antineoplastic agent;
metabolite		202320231.0low000001
narlaprevir
2
azabicyclohexane;
cyclopropanes;
pyrrolidinecarboxamide;
secondary carboxamide;
sulfone;
tertiary carboxamide;
ureas		anticoronaviral agent;
antiviral drug;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
hepatitis C protease inhibitor		201920233.0medium000011
teneligliptin
1
amino acid amide202320231.0medium000001
dextrothyroxine
1
202320231.0low000001
veliparib
1
benzimidazolesEC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor202320231.0low000001
pf 03491390
1
202320231.0low000001
alloin
1
anthracenes;
C-glycosyl compound;
cyclic ketone;
phenols		laxative;
metabolite		202320231.0high000001
mdv 3100
1
(trifluoromethyl)benzenes;
benzamides;
imidazolidinone;
monofluorobenzenes;
nitrile;
thiocarbonyl compound		androgen antagonist;
antineoplastic agent		202320231.0low000001
bms-650032
3
oligopeptide201920233.7low000021
rg 7128
1
202320231.0low000001
oritavancin
1
disaccharide derivative;
glycopeptide;
semisynthetic derivative		antibacterial drug;
antimicrobial agent		202320231.0low000001
pevonedistat
1
cyclopentanols;
indanes;
pyrrolopyrimidine;
secondary amino compound;
sulfamidate		antineoplastic agent;
apoptosis inducer		202320231.0low000001
uk 453,061
1
aromatic ether202320231.0low000001
N-(2-aminophenyl)-2-pyrazinecarboxamide
1
aromatic amide202320231.0high000001
tegobuvir
1
202320231.0low000001
pf-429242
1
202320231.0low000001
olaparib
1
cyclopropanes;
monofluorobenzenes;
N-acylpiperazine;
phthalazines		antineoplastic agent;
apoptosis inducer;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor		202320231.0low000001
cx 4945
1
202320231.0low000001
pci 34051
1
indolecarboxamide202320231.0low000001
mk-7009
5
azamacrocycle;
carbamate ester;
cyclopropanes;
N-sulfonylcarboxamide;
pyrrolidinecarboxamide		antiviral drug;
hepatitis C protease inhibitor		2010201910.0medium000230
lomibuvir
1
thiophenecarboxylic acid202320231.0low000001
delanzomib
1
C-terminal boronic acid peptide;
phenylpyridine;
secondary alcohol;
threonine derivative		antineoplastic agent;
apoptosis inducer;
proteasome inhibitor		202320231.0low000001
pitavastatin(1-)
1
hydroxy monocarboxylic acid anion202320231.0high000001
simeprevir
6
azamacrocycle;
lactam		2010201912.0high000330
GRL-0617
1
benzamides;
naphthalenes;
secondary carboxamide;
substituted aniline		anticoronaviral agent;
protease inhibitor		202320231.0low000001
N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester
1
carbamate ester202320231.0low000001
niraparib
1
2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamideantineoplastic agent;
apoptosis inducer;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
radiosensitizing agent		202320231.0low000001
jzl 184
1
benzodioxoles202320231.0low000001
gsk 650394
1
phenylpyridine202320231.0low000001
oprozomib
1
202320231.0low000001
az 960
1
202320231.0low000001
robotnikinin
1
2011201113.0medium000010
golgicide a
1
diastereoisomeric mixturecis-Golgi ArfGEF GBF inhibitor202320231.0low000001
cobicistat
1
1,3-thiazoles;
carbamate ester;
monocarboxylic acid amide;
morpholines;
ureas		P450 inhibitor202320231.0low000001
bms-790052
1
biphenyls;
carbamate ester;
carboxamide;
imidazoles;
valine derivative		antiviral drug;
nonstructural protein 5A inhibitor		202320231.0low000001
gs-9451
1
201920195.0low000010
ixazomib
1
benzamides;
boronic acids;
dichlorobenzene;
glycine derivative		antineoplastic agent;
apoptosis inducer;
drug metabolite;
orphan drug;
proteasome inhibitor		202320231.0low000001
ucph 101
1
202320231.0low000001
bi 201335
2
201920195.0low000020
5-(3-methylsulfonylphenyl)-4-[(1-methyl-5-tetrazolyl)thio]thieno[2,3-d]pyrimidine
1
aryl sulfide;
thienopyrimidine		202320231.0low000001
baricitinib
1
azetidines;
nitrile;
pyrazoles;
pyrrolopyrimidine;
sulfonamide		anti-inflammatory agent;
antirheumatic drug;
antiviral agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
immunosuppressive agent		202320231.0low000001
KOM70144
1
acetamides;
benzamides;
naphthalenes;
secondary carboxamide		anticoronaviral agent;
protease inhibitor		202320231.0high000001
e-52862
1
202320231.0low000001
ly2811376
1
202320231.0low000001
anagliptin
1
amino acid amide202320231.0low000001
tmc647055
1
201920195.0medium000010
gardiquimod
1
202320231.0low000001
grazoprevir
3
aromatic ether;
azamacrocycle;
carbamate ester;
cyclopropanes;
lactam;
N-sulfonylcarboxamide;
quinoxaline derivative		antiviral drug;
hepatitis C protease inhibitor;
hepatoprotective agent		201920233.7low000021
abt-450
2
201920233.0low000011
letermovir
1
202320231.0low000001
sofosbuvir
1
isopropyl ester;
L-alanyl ester;
nucleotide conjugate;
organofluorine compound;
phosphoramidate ester		antiviral drug;
hepatitis C protease inhibitor;
prodrug		202320231.0low000001
5-(4-amino-1-propan-2-yl-3-pyrazolo[3,4-d]pyrimidinyl)-1,3-benzoxazol-2-amine
1
benzoxazole202320231.0low000001
blz 945
1
202320231.0medium000001
azd3839
1
202320231.0medium000001
pf 3084014
1
202320231.0low000001
unc 0638
1
quinazolines202320231.0low000001
gs-9620
1
202320231.0low000001
n-((5-(methanesulfonyl)pyridin-2-yl)methyl)-6-methyl-5-(1-methyl-1h-pyrazol-5-yl)-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamide
1
202320231.0low000001
bms 708163
1
oxadiazole;
ring assembly		202320231.0low000001
jq1 compound
1
carboxylic ester;
organochlorine compound;
tert-butyl ester;
thienotriazolodiazepine		angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
bromodomain-containing protein 4 inhibitor;
cardioprotective agent;
ferroptosis inducer		202320231.0low000001
1-(5-((2,4-difluorophenyl)thio)-4-nitrothiophen-2-yl)ethanone
1
202320231.0low000001
gsk525762a
1
benzodiazepine202320231.0low000001
ML240
1
aromatic amine;
aromatic ether;
benzimidazoles;
primary amino compound;
quinazolines;
secondary amino compound		antineoplastic agent202320231.0low000001
birinapant
1
dipeptide202320231.0low000001
ly2886721
1
202320231.0medium000001
nms-p118
1
202320231.0medium000001
tubastatin a
1
hydroxamic acid;
pyridoindole;
tertiary amino compound		EC 3.5.1.98 (histone deacetylase) inhibitor202320231.0low000001
pracinostat
1
benzimidazole;
hydroxamic acid;
olefinic compound;
tertiary amino compound		antimalarial;
antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor		202320231.0low000001
spautin-1
1
202320231.0low000001
ldn 57444
1
202320231.0low000001
gsk1210151a
1
imidazoquinoline202320231.0low000001
i-bet726
1
202320231.0low000001
acy-1215
1
pyrimidinecarboxylic acid202320231.0low000001
cudc-907
1
202320231.0low000001
mobic
1
1,3-thiazoles;
benzothiazine;
monocarboxylic acid amide		analgesic;
antirheumatic drug;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug		202320231.0low000001
tipranavir
1
sulfonamideantiviral drug;
HIV protease inhibitor		202320231.0low000001
tasquinimod
1
202320231.0low000001
gsk1265744
1
difluorobenzene;
monocarboxylic acid amide;
organic heterotricyclic compound;
secondary carboxamide		HIV-1 integrase inhibitor202320231.0low000001
abt-267
1
aromatic amide;
carbamate ester;
dipeptide;
pyrrolidines		antiviral drug;
hepatitis C virus nonstructural protein 5A inhibitor		202320231.0low000001
abt-333
1
aromatic ether;
naphthalenes;
pyrimidone;
sulfonamide		antiviral drug;
nonnucleoside hepatitis C virus polymerase inhibitor		202320231.0low000001
rgfp966
1
202320231.0low000001
rg2833
1
202320231.0medium000001
pi-1840
1
202320231.0medium000001
acy-738
1
202320231.0medium000001
pelabresib
1
monochlorobenzenes;
organic heterotricyclic compound;
primary carboxamide		antineoplastic agent;
bromodomain-containing protein 4 inhibitor		202320231.0low000001
gs-5806
1
202320231.0low000001
doravirine
1
202320231.0low000001
gn6958
1
202320231.0high000001
vx-787
1
202320231.0low000001
ledipasvir
1
azaspiro compound;
benzimidazole;
bridged compound;
carbamate ester;
carboxamide;
fluorenes;
imidazoles;
L-valine derivative;
N-acylpyrrolidine;
organofluorine compound		antiviral drug;
hepatitis C protease inhibitor		202320231.0low000001
gs-5816
1
carbamate ester;
ether;
imidazoles;
L-valine derivative;
N-acylpyrrolidine;
organic heteropentacyclic compound;
ring assembly		antiviral drug;
hepatitis C virus nonstructural protein 5A inhibitor		202320231.0low000001
g007-lk
1
202320231.0low000001
4-((1-butyl-3-phenylureido)methyl)-n-hydroxybenzamide
1
202320231.0low000001
selinexor
1
202320231.0low000001
verdinexor
1
202320231.0low000001
cb-839
1
202320231.0low000001
mk-8742
1
carbamate ester;
imidazoles;
L-valine derivative;
N-acylpyrrolidine;
organic heterotetracyclic compound;
ring assembly		antiviral drug;
hepatitis C virus nonstructural protein 5A inhibitor;
hepatoprotective agent		202320231.0low000001
atglistatin
1
202320231.0low000001
xen445
1
202320231.0high000001
santacruzamate a
1
organonitrogen compound;
organooxygen compound		202320231.0medium000001
ldc4297
1
aromatic ether;
piperidines;
pyrazoles;
pyrazolotriazine;
secondary amino compound		antineoplastic agent;
antiviral agent;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor		202320231.0medium000001
enasidenib
1
1,3,5-triazines;
aminopyridine;
aromatic amine;
organofluorine compound;
secondary amino compound;
tertiary alcohol		antineoplastic agent;
EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor		202320231.0low000001
s 8932
1
aromatic amine;
C-nucleoside;
carboxylic ester;
nitrile;
phosphoramidate ester;
pyrrolotriazine		anticoronaviral agent;
antiviral drug;
prodrug		202320231.0low000001
entecavir
1
2-aminopurines;
oxopurine;
primary alcohol;
secondary alcohol		antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor		202320231.0low000001
acyclovir
1
2-aminopurines;
oxopurine		antimetabolite;
antiviral drug		202320231.0low000001
nu 1025
1
phenols;
quinazolines		EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor202320231.0low000001
didanosine
1
purine 2',3'-dideoxyribonucleosideantimetabolite;
antiviral drug;
EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor;
geroprotector;
HIV-1 reverse transcriptase inhibitor		202320231.0low000001
ganciclovir
1
2-aminopurines;
oxopurine		antiinfective agent;
antiviral drug		202320231.0low000001
valacyclovir
1
L-valyl esterantiviral drug202320231.0low000001
penciclovir
1
2-aminopurines;
propane-1,3-diols		antiviral drug202320231.0low000001
4-hydroxyquinazoline
1
quinazolines202320231.0low000001
tegaserod
1
carboxamidine;
guanidines;
hydrazines;
indoles		gastrointestinal drug;
serotonergic agonist		202320231.0low000001
norclozapine
1
dibenzodiazepine;
organochlorine compound;
piperazines		delta-opioid receptor agonist;
metabolite;
serotonergic antagonist		202320231.0low000001
pemetrexed
1
N-acyl-L-glutamic acid;
pyrrolopyrimidine		antimetabolite;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
EC 2.1.1.45 (thymidylate synthase) inhibitor;
EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor		202320231.0low000001
aprepitant
1
(trifluoromethyl)benzenes;
cyclic acetal;
morpholines;
triazoles		antidepressant;
antiemetic;
neurokinin-1 receptor antagonist;
peripheral nervous system drug;
substance P receptor antagonist		202320231.0low000001
azilsartan
1
1,2,4-oxadiazole;
aromatic ether;
benzimidazolecarboxylic acid		angiotensin receptor antagonist;
antihypertensive agent		202320231.0low000001
hesperadin
1
202320231.0low000001
6-bromoindirubin-3'-acetoxime
1
202320231.0high000001
n'-(3,4-dihydroxybenzylidene)-3-hydroxy-2-naphthahydrazide
1
catechols;
hydrazide;
hydrazone;
naphthols		EC 3.6.5.5 (dynamin GTPase) inhibitor202320231.0medium000001
XL413
1
benzofuropyrimidine;
organochlorine compound;
pyrrolidines		antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor		202320231.0medium000001
me0328
1
202320231.0medium000001
nvp-tnks656
1
202320231.0medium000001
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
carbamates
1
amino-acid anion2014201410.0low000010
chloroquine
1
aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug		202020204.0low000010
ketoconazole
1
dichlorobenzene;
dioxolane;
ether;
imidazoles;
N-acylpiperazine;
N-arylpiperazine		2014201410.0low100010
methadone
1
benzenes;
diarylmethane;
ketone;
tertiary amino compound		2014201410.0low100010
midazolam
1
imidazobenzodiazepine;
monofluorobenzenes;
organochlorine compound		anticonvulsant;
antineoplastic agent;
anxiolytic drug;
apoptosis inducer;
central nervous system depressant;
GABAA receptor agonist;
general anaesthetic;
muscle relaxant;
sedative		2013201311.0low100010
omeprazole
1
aromatic ether;
benzimidazoles;
pyridines;
sulfoxide		2014201410.0low100010
alanine
2
alanine zwitterion;
alanine;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid		EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor;
fundamental metabolite		201220208.0low000020
aspartic acid
1
aspartate family amino acid;
aspartic acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
mouse metabolite;
neurotransmitter		2012201212.0low000010
lysine
1
aspartate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
lysine;
organic molecular entity;
proteinogenic amino acid		algal metabolite;
anticonvulsant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite		2012201212.0low000010
carbostyril
1
monohydroxyquinoline;
quinolone		bacterial xenobiotic metabolite201620168.0low100010
adenosine monophosphate
1
adenosine 5'-phosphate;
purine ribonucleoside 5'-monophosphate		adenosine A1 receptor agonist;
cofactor;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
EC 3.1.3.11 (fructose-bisphosphatase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical		202020204.0low000010
leucine
6
amino acid zwitterion;
L-alpha-amino acid;
leucine;
proteinogenic amino acid;
pyruvate family amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite		2010201612.2low000150
valine
2
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid;
valine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite		201220217.5low100011
arginine
1
arginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical		2012201212.0low000010
thiazoles
4
1,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene		2011201611.0low000040
pyrazines
1
diazine;
pyrazines		Daphnia magna metabolite202020204.0low000010
deoxycytidine
9
pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		2010201610.7low800270
glutamic acid
1
glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical		2012201212.0low000010
ribavirin
16
1-ribosyltriazole;
aromatic amide;
monocarboxylic acid amide;
primary carboxamide		anticoronaviral agent;
antiinfective agent;
antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor		201020219.5low12001141
lopinavir
1
amphetamines;
dicarboxylic acid diamide		anticoronaviral agent;
antiviral drug;
HIV protease inhibitor		202020204.0low000010
proline
60
amino acid zwitterion;
glutamine family amino acid;
L-alpha-amino acid;
proline;
proteinogenic amino acid		algal metabolite;
compatible osmolytes;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite		201020219.8low30005523
darunavir
1
carbamate ester;
furofuran;
sulfonamide		antiviral drug;
HIV protease inhibitor		202120213.0low000001
ritonavir
20
1,3-thiazoles;
carbamate ester;
carboxamide;
L-valine derivative;
ureas		antiviral drug;
environmental contaminant;
HIV protease inhibitor;
xenobiotic		201020218.8low16001181
saquinavir
1
L-asparagine derivative;
quinolines		antiviral drug;
HIV protease inhibitor		202120213.0low000001
favipiravir
1
hydroxypyrazine;
organofluorine compound;
primary carboxamide		anticoronaviral agent;
antiviral drug;
EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor		202020204.0low000010
ranitidine
1
C-nitro compound;
furans;
organic sulfide;
tertiary amino compound		anti-ulcer drug;
drug allergen;
environmental contaminant;
H2-receptor antagonist;
xenobiotic		2014201410.0low100010
telaprevir
7
cyclopentapyrrole;
cyclopropanes;
oligopeptide;
pyrazines		antiviral drug;
hepatitis C protease inhibitor;
peptidomimetic		2010201412.1low000160
vitamin k semiquinone radical
1
2013201311.0low100010
biln 2061
1
2014201410.0low000010
bms-650032
2
oligopeptide201420207.0low000020
rg 7128
9
2010201610.7high800270
mk-7009
4
azamacrocycle;
carbamate ester;
cyclopropanes;
N-sulfonylcarboxamide;
pyrrolidinecarboxamide		antiviral drug;
hepatitis C protease inhibitor		2010201213.0medium000130
bi 201335
3
2011201611.3low000030
sofosbuvir
1
isopropyl ester;
L-alanyl ester;
nucleotide conjugate;
organofluorine compound;
phosphoramidate ester		antiviral drug;
hepatitis C protease inhibitor;
prodrug		202120213.0low000001
warfarin
1
benzenes;
hydroxycoumarin;
methyl ketone		2013201311.0low100010
ledipasvir
1
azaspiro compound;
benzimidazole;
bridged compound;
carbamate ester;
carboxamide;
fluorenes;
imidazoles;
L-valine derivative;
N-acylpyrrolidine;
organofluorine compound		antiviral drug;
hepatitis C protease inhibitor		202020204.0low000010
s 8932
1
aromatic amine;
C-nucleoside;
carboxylic ester;
nitrile;
phosphoramidate ester;
pyrrolotriazine		anticoronaviral agent;
antiviral drug;
prodrug		202020204.0low000010
cyclosporine
3
201320208.0low100030
neopterin
1
2011201113.0low100010
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
Chronic Hepatitis C0
1
2011201113.0low000010
Hepatitis C1
3
201020199.0low000120
Hepatitis C, Chronic1
1
2011201113.0low000010
Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted0
3
201020199.0low000120
2019 Novel Coronavirus Disease0
4
202020213.8low100031
Cancer of Liver0
1
2011201113.0low000010
Carcinoma, Hepatocellular0
1
2011201113.0low000010
Carcinoma, Lewis Lung0
1
201520159.0low000010
Chronic Hepatitis C0
24
2010202110.2high17003201
Cirrhosis, Liver0
4
201620216.2low300031
Hepatitis C0
13
2010202010.2medium5001120
Hepatitis C, Chronic0
24
2010202110.2high17003201
Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted0
13
2010202010.2medium5001120
Hepatocellular Carcinoma0
1
2011201113.0low000010
Inflammation0
1
2011201113.0low100010
Innate Inflammatory Response0
1
2011201113.0low100010
Insulin Resistance0
1
2010201014.0low100100
Insulin Sensitivity0
1
2010201014.0low100100
Liver Cirrhosis0
4
201620216.2low300031
Liver Neoplasms0
1
2011201113.0low000010
Recrudescence0
1
2012201212.0low100010

Safety/Toxicity (4)

ArticleYear
Pharmacokinetics, Safety, and Tolerability of Ravidasvir, with and without Danoprevir/Ritonavir, in Healthy Subjects.
Antimicrobial agents and chemotherapy, , 09-17, Volume: 65, Issue:10		2021
Efficacy and safety of danoprevir plus sofosbuvir in GT 1, 2, 3, or 6 chronic hepatitis C patients with or without cirrhosis in China.
Medicine, , Jun-18, Volume: 100, Issue:24		2021
Efficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null responders.
Antimicrobial agents and chemotherapy, , Volume: 58, Issue:2		2014
Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients.
Journal of hepatology, , Volume: 55, Issue:5		2011

Pharmacokinetics (7)

ArticleYear
Pharmacokinetics, Safety, and Tolerability of Ravidasvir, with and without Danoprevir/Ritonavir, in Healthy Subjects.
Antimicrobial agents and chemotherapy, , 09-17, Volume: 65, Issue:10		2021
A pharmacokinetic/viral kinetic model to evaluate the treatment effectiveness of danoprevir against chronic HCV.
Antiviral therapy, , Volume: 20, Issue:5		2015
Effect of meal and antisecretory agents on the pharmacokinetics of danoprevir/ritonavir in healthy volunteers.
The Journal of pharmacy and pharmacology, , Volume: 66, Issue:1		2014
Effect of ritonavir-boosted danoprevir, a potent hepatitis C virus protease inhibitor, on the pharmacokinetics of methadone in healthy subjects undergoing methadone maintenance therapy.
Pharmacotherapy, , Volume: 34, Issue:3		2014
Pharmacokinetics of a three-way drug interaction between danoprevir, ritonavir and the organic anion transporting polypeptide (OATP) inhibitor ciclosporin.
Clinical pharmacokinetics, , Volume: 52, Issue:9		2013
Impact of low-dose ritonavir on danoprevir pharmacokinetics: results of computer-based simulations and a clinical drug-drug interaction study.
Clinical pharmacokinetics, , Jul-01, Volume: 51, Issue:7		2012
Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients.
Journal of hepatology, , Volume: 55, Issue:5		2011

Bioavailability (4)

ArticleYear
Estimating Efflux Transporter-Mediated Disposition of Molecules beyond the Rule of Five (bRo5) Using Transporter Gene Knockout Rats.
Biological & pharmaceutical bulletin, , Mar-01, Volume: 43, Issue:3		2020
Characterization of the transmembrane transport and absolute bioavailability of the HCV protease inhibitor danoprevir.
Clinical pharmacokinetics, , Volume: 54, Issue:5		2015
Two-way interaction study between ritonavir boosted danoprevir, a potent HCV protease inhibitor, and ketoconazole in healthy subjects.
International journal of clinical pharmacology and therapeutics, , Volume: 52, Issue:2		2014
Physiological modeling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasible.
Biopharmaceutics & drug disposition, , Volume: 32, Issue:5		2011

Dosage (6)

ArticleYear
Effect of ritonavir-boosted danoprevir, a potent hepatitis C virus protease inhibitor, on the pharmacokinetics of methadone in healthy subjects undergoing methadone maintenance therapy.
Pharmacotherapy, , Volume: 34, Issue:3		2014
A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail.
European journal of clinical pharmacology, , Volume: 69, Issue:11		2013
Impact of low-dose ritonavir on danoprevir pharmacokinetics: results of computer-based simulations and a clinical drug-drug interaction study.
Clinical pharmacokinetics, , Jul-01, Volume: 51, Issue:7		2012
Physiological modeling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasible.
Biopharmaceutics & drug disposition, , Volume: 32, Issue:5		2011
Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients.
Journal of hepatology, , Volume: 55, Issue:5		2011
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial.
Lancet (London, England), , Oct-30, Volume: 376, Issue:9751		2010

Interactions (3)

ArticleYear
Pharmacokinetics of a three-way drug interaction between danoprevir, ritonavir and the organic anion transporting polypeptide (OATP) inhibitor ciclosporin.
Clinical pharmacokinetics, , Volume: 52, Issue:9		2013
Impact of low-dose ritonavir on danoprevir pharmacokinetics: results of computer-based simulations and a clinical drug-drug interaction study.
Clinical pharmacokinetics, , Jul-01, Volume: 51, Issue:7		2012
Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon α-2a and ribavirin in patients with hepatitis C.
The Journal of infectious diseases, , Aug-15, Volume: 204, Issue:4		2011